预约演示
更新于：2026-04-25
Cilofexor tromethamine
更新于：2026-04-25
概要
基本信息
在研机构- |
最高研发阶段终止临床3期 |
首次获批日期- |
最高研发阶段(中国)- |
特殊审评- |
登录后查看时间轴
结构/序列
分子式C32H33Cl3N4O8 |
InChIKeyCUWTTWVBVUZPAP-UHFFFAOYSA-N |
CAS号2253764-93-9 |
关联
12
项与 Cilofexor tromethamine 相关的临床试验NCT04060147
A Proof-of-Concept, Open-Label Study Evaluating the Safety and Tolerability of Cilofexor in Subjects With Primary Sclerosing Cholangitis (PSC) and Compensated Cirrhosis
The primary objective of this study is to assess the safety and tolerability of escalating doses of cilofexor (CILO) in participants with primary sclerosing cholangitis (PSC) and compensated cirrhosis.
开始日期2019-10-17 |
申办/合作机构 |
NCT03987074
A Proof of Concept, Open-Label Study Evaluating the Safety, Tolerability, and Efficacy of Monotherapy and Combination Regimens in Subjects With Nonalcoholic Steatohepatitis (NASH)
The primary objective of this study is to evaluate the safety and tolerability of study drug(s) in participants with nonalcoholic steatohepatitis (NASH).
开始日期2019-07-29 |
申办/合作机构 |
ACTRN12619000655145
A Phase 1 Open-Label, Parallel-Group, Two-Treatment, Single-Dose Study to Evaluate the Pharmacokinetics of GS-9674 and GS-0976 in Subjects with Normal Renal Function and Severe Renal Impairment
开始日期2019-07-24 |
申办/合作机构 |
100 项与 Cilofexor tromethamine 相关的临床结果
登录后查看更多信息
100 项与 Cilofexor tromethamine 相关的转化医学
登录后查看更多信息
100 项与 Cilofexor tromethamine 相关的专利（医药）
登录后查看更多信息
68
项与 Cilofexor tromethamine 相关的文献（医药）2026-04-01·Liver International
An Update on Bile Acid‐Regulated Signalling in the Pathogenesis of Metabolic Dysfunction‐Associated Steatotic Liver Disease
Review
作者: Wang, Li ; Wen, Yi ; Wang, Lu ; Wang, Hong‐Lian ; Chen, Chen ; Zhao, Chang‐Ying ; Shi, Jiang‐Shan ; Wu, Li‐Juan
ABSTRACT:
Metabolic dysfunction‐associated steatotic liver disease (MASLD) is a common metabolic disorder with rising global incidence without effective treatment. Emerging evidence highlights bile acids (BAs) as pivotal signalling molecules that modulate genes involved in their own metabolism and lipid homeostasis in hepatic and extrahepatic tissues, thereby influencing MASLD pathogenesis. These regulatory effects are primarily driven by the activation of nuclear receptors, including the farnesoid X receptor (FXR), vitamin D receptor (VDR), pregnane X receptor (PXR), and by the membrane‐bound G protein‐coupled receptors such as Takeda G protein‐coupled receptor 5 (TGR5) and sphingosine‐1‐phosphate receptor 2 (S1PR2). The distinct roles of these BA receptor‐dependent signalling pathways in lipid homeostasis underscore their importance in MASLD development. Pharmacological strategies targeting BA‐regulated pathways, particularly the FXR activation, have shown promise in MASLD treatment. Several FXR agonists, including obeticholic acid (OCA), cilofexor, and tropifexor, have progressed to clinical trials, demonstrating potential therapeutic efficacy. Additionally, recent studies identified several natural compounds—such as hyperoside, kaempferol, and salidroside—that exhibited direct or indirect FXR‐modulating properties, suggesting their potential utility for novel anti‐MASLD drug development. Further research into BA signalling mechanisms and the exploration of targeted therapies may provide novel and effective MASLD therapy.
2026-01-01·EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY
FXR-targeted drug discovery: Recent advances and therapeutic perspectives
Review
作者: Zhou, Xiangyang ; Cao, Yu ; Shan, Lianhai ; Mao, Wu-Yu ; Shang, Weidong ; Li, Qian ; Liu, Zihang
Farnesoid X Receptor (FXR), a pivotal member of the nuclear receptor superfamily, plays a central role in the regulation of crucial physiological processes. These processes encompass bile acid homeostasis, inflammatory responses, fibrosis, as well as lipid and glucose metabolism. Given its extensive physiological functions, FXR has become an extremely promising therapeutic target for bile acid metabolism disorders. In recent years, the progress in medicinal chemistry has significantly expedited the development of FXR agonists. In 2016, obeticholic acid (OCA) received approval from FDA for marketing. As the first small-molecule drug targeting FXR for primary biliary cholangitis (PBC), its approval has spurred the advancement of multiple FXR agonists with diverse chemical structures into clinical trials. Notable candidates include Tropifexor (for non-alcoholic steatohepatitis, NASH), Cilofexor (for PBC), and Nidufexor (for diabetic nephropathy). This review delineates the structural features and biological functions of FXR, analyzes molecular mechanisms underpinning its signal transduction pathways and disease pathogenesis, and highlights molecular design strategies and structure-activity relationship (SAR) advancements in FXR agonists. These insights aim to provide a theoretical foundation for rationally designing novel, potent FXR agonists.
2026-01-01·The Lancet Gastroenterology & Hepatology
Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial
Article
作者: Caldwell, Stephen ; Vuppalanchi, Raj ; Invernizzi, Pietro ; Salminen, Kimmo ; Alani, Muhsen ; Bolbolan, Shahla ; Montano-Loza, Aldo J ; Joshi, Deepak ; Farkkila, Martti ; Genovese, Mark C ; Tanaka, Atsushi ; Xu, Jun ; Barchuk, William T ; Thorburn, Douglas ; Trauner, Michael ; Liu, Xiangyu ; Goodman, Zachary ; Levy, Cynthia ; Danta, Mark ; Gordon, Stuart C ; Bowlus, Christopher L ; Hinrichsen, Holger ; Yimam, Kidist ; Watkins, Timothy R ; Isayama, Hiroyuki ; Lu, Xiaomin ; Gallegos-Orozco, Juan F ; Crans, Gerald ; Boyette, Lisa ; Zhu, Kaiyi
BACKGROUND:
There is currently no pharmacological therapy proven to alter the natural course of primary sclerosing cholangitis (PSC). The PRIMIS trial evaluated the efficacy and harms of the farnesoid X-activated receptor agonist cilofexor in participants with non-cirrhotic PSC.
METHODS:
In this phase 3, double-blind, placebo-controlled, multicentre trial (205 sites across 16 countries), adults aged 18-75 years with non-cirrhotic (F0-F3 [Ludwig classification]) large-duct PSC were randomly assigned (2:1) via an interactive web response system to receive cilofexor 100 mg or placebo (identical in appearance) orally once daily for 96 weeks. Randomisation was stratified by ursodeoxycholic acid use (yes or no) and the presence of bridging fibrosis (F3 vs F0-F2), with a block size of six within each stratum. Participants, personnel directly involved in the conduct of the study, and outcome assessors were masked to treatment assignment. The primary endpoint was the proportion of participants with histological progression of liver fibrosis (a stage increase of one or more [Ludwig classification]) at week 96. After study termination, the primary endpoint analysis set was amended to include all participants in the harms analysis set (all who received at least one dose of the study drug) who had biopsy data at baseline and week 96. This trial is complete (ClincalTrials.gov, NCT03890120).
FINDINGS:
Between June 13, 2019, and July 22, 2021, 419 participants were randomly assigned, and 416 were included in the full and harms analysis sets (cilofexor: n=277; placebo: n=139); 257 (62%) men and 159 (38%) women. The study was terminated early on Sept 26, 2022, after a planned interim futility analysis after 160 patients had reached 96 weeks of follow-up indicated a 6·8% probability of detecting a significant difference between cilofexor over placebo (futility boundary ≤10%). In the final analysis of the primary endpoint, for which 133 patients in the cilofexor group and 64 in the placebo group had liver biopsy results available, fibrosis progression occurred in 41 (31%) participants in the cilofexor group and 21 (33%) in the placebo group at week 96 (treatment difference -1·4% [95% CI -15·2 to 12·3]; p=0·42). The most common adverse events were pruritus (cilofexor: 136 [49%] of 277 patients; placebo: 50 [36%] of 139 patients; grade 3 or higher in 11 [4%] patients in the cilofexor group and one [1%] patient in the placebo group), COVID-19 (cilofexor: 65 [23%]; placebo: 26 [19%]), and upper abdominal pain (cilofexor: 40 [14%]; placebo 20 [14%]). The proportion of serious adverse events was similar between groups (cilofexor: 53 [19%]; placebo: 26 [19%]). There were no treatment-related deaths.
INTERPRETATION:
Cilofexor did not significantly reduce the rate of fibrosis progression (vs placebo) in participants with non-cirrhotic PSC. A greater percentage of cilofexor-treated participants had pruritus than placebo-treated participants; this study provides valuable harms data for cilofexor and other drugs in its class.
FUNDING:
Gilead Sciences.
79
项与 Cilofexor tromethamine 相关的新闻（医药）2026-04-21
THE LANCET Gastroenterology & Hepatology. Volume 11Number1
柳叶刀胃肠病学与肝病学 11卷 1期
https://www.thelancet.com/journals/langas/issue/current
EDITORIAL(社论)
1
Accelerating MASH trials: from biopsy to biomarkers
加速MASH（代谢障碍相关脂肪性肝炎）试验：从活检到生物标志物
The Lancet Gastroenterology & Hepatology
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p1
COMMENT（述评）
2
Optimising treatment in Crohn's disease: is the main issue early versus late or biologic naive versus biologic experienced?
优化克罗恩病的治疗：主要问题在于早期治疗与晚期治疗，还是生物制剂初治患者与生物制剂经治患者？
Marte Lie Høivik
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p2
3
Ileal bile acid transporter inhibitors for cholestatic pruritus in primary biliary cholangitis
针对原发性胆汁性胆管炎中胆汁淤积性瘙痒的回肠胆汁酸转运蛋白抑制剂
Ansgar W Lohse,David N Assis
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p3
4
Dual targeting of TNF and IL-23 by a bispecific antibody in ulcerative colitis
双特异性抗体在溃疡性结肠炎中同时靶向TNF和IL-23
Raja Atreya,Markus F Neurath
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p5
5
The essential medicines list for inflammatory bowel disease: time to raise the standards of global care
炎症性肠病基本药物清单：是时候提高全球护理标准了
Nanne K de Boer,Richard B Gearry,Charles N Bernstein,Rupa Banerjee,David T Rubin,Gilaad G Kaplanon behalf of the Globalization Cluster of the International Organization of IBD
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p7
NEWS（新闻）
6
The Liver Meeting 2025
2025年肝脏会议
Rob Brierley
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p10
IN FOCUS（焦点）
7
Food Matters
食物很重要
Dietary management of constipation: time for clinical guidelines to catch up with evidence
便秘的饮食治疗：是时候让临床指南跟上证据的步伐了
Eirini Dimidi,Kevin Whelan
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p11
ARTICLES（论著）
8
Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study
维多珠单抗在早期和晚期克罗恩病中的应用（LOVE-CD）：一项4期开放性队列研究
Geert R D'Haens,Mark Löwenberg,Filip Baert,Peter Bossuyt,Tamás Molnár,Frank Hoentjen,Esmé Clasquin,Krisztina B Gecse,Melanie S Hulshoff,Gert De Hertogh,Matthias Lenfant,Lotte Oldenburg,Séverine Vermeire
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p12
9
Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): 利尼西巴特治疗原发性胆汁性胆管炎和胆汁淤积性瘙痒患者（GLISTEN）：一项随机、多中心、双盲、安慰剂对照的3期试验
a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
Gideon M Hirschfield,Christopher L Bowlus,David E J Jones,Andreas E Kremer,Marlyn J Mayo,Atsushi Tanaka,Pietro Andreone,Jidong Jia,Qinglong Jin,Ricardo U Macías-Rodríguez,Alexander R Cobitz,Brooke M Currie,Ciara Gorey,Ivana Lazic,Danielle Podmore,Andrea Ribeiro,Jennifer B Shannon,Brandon Swift,Megan M McLaughlin,Cynthia Levyfor the GLISTEN Study Group
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p22
10
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial
SOR102（一种口服双特异性肿瘤坏死因子和白细胞介素-23抑制剂）在健康受试者和溃疡性结肠炎患者中的安全性和药代动力学：一项首次人体、双盲、随机、安慰剂对照的1期试验
Vipul Jairath,Silvio Danese,Geert R D’Haens,Brian G Feagan,Laurent Peyrin-Biroulet,Bruce E Sands,Ingrid Gaemers,Matt Westfall,Allyson Q Terry,Kevin J Roberts,Sara Barbat,Pamela Wedel,Jacqueline M Benson,Carlos Sattler
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p34
11
Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial
西洛芬酸在非肝硬化原发性硬化性胆管炎中的应用（PRIMIS）：一项随机、双盲、多中心、安慰剂对照的3期试验
Michael Trauner,Cynthia Levy,Atsushi Tanaka,Zachary Goodman,Douglas Thorburn,Deepak Joshi,Kimmo Salminen,Kidist Yimam,Hiroyuki Isayama,Aldo J Montano-Loza,Stephen Caldwell,Mark Danta,Martti Farkkila,Juan F Gallegos-Orozco,Stuart C Gordon,Holger Hinrichsen,Pietro Invernizzi,Raj Vuppalanchi,Kaiyi Zhu,Jun Xu,Xiangyu Liu,Xiaomin Lu,Gerald Crans,Shahla Bolbolan,Lisa Boyette,Muhsen Alani,William T Barchuk,Timothy R Watkins,Mark C Genovese,Christopher L Bowlus
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p46
REVIEW（综述）
12
Age-related changes of the gastrointestinal tract
胃肠道的年龄相关变化
Alberto Pilotto,Carlo Custodero,Lucilla Crudele,Wanda Morganti,Nicola Veronese,Marilisa Franceschi
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p59
13
Fatigue in people with primary biliary cholangitis: a position paper from the European Reference Network for Rare Liver Diseases
原发性胆汁性胆管炎患者的疲劳问题：欧洲罕见肝病参考网络立场文件
Ozgur M Koc,Anne-Kristin Toussaint,Aurelie Untas,Piotr Milkiewicz,Henriette Ytting,Laura Buck,David E Jones,Gideon Hirschfield,Angela Leburgue,Christoph Schramm,Frederik Nevens,Adriaan J van der Meer,Alessio Gerussi,Jef Verbeek
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p71
THE LANCET Gastroenterology & Hepatology. Volume 11Number2
柳叶刀胃肠病学与肝病学 11卷 2期
https://www.thelancet.com/journals/langas/issue/current
EDITORIAL(社论)
1
ACIP's HBV birth-dose vaccine recommendations: a fiasco
美国免疫接种咨询委员会（ACIP）的乙肝疫苗出生剂量推荐：一场闹剧
The Lancet Gastroenterology & Hepatology
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p87
COMMENT（述评）
2
Expanding the therapeutic arsenal for paediatric ulcerative colitis
扩充儿童溃疡性结肠炎的治疗武器库
Stephanie A Vuijk,Esmée H Boute,Lissy de Ridder
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p88
3
Closing the Middle East and north Africa representation gap in clinical trials in inflammatory bowel disease
缩小炎症性肠病临床试验中中东和北非地区代表不足的差距
Mohammad Shebab,Ahmed Al-Hindawi,Shane W Goodwin,Yuhong Yuan,Talat Bessissow,Laurent Peyrin-Biroulet,Vipul Jairath
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p89
4
Colorectal cancer screening in LGBTQIA+ people: an urgent call for equity
对LGBTQIA+人群进行结直肠癌筛查：迫切呼吁公平
Vidhi Singh,Jayraan Badiee,Alexander Goldowsky,David Russo,Folasade P May
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p91
CORRESPONDENCE（读者来信）
5
Efficacy differentiation of sterile faecal filtrates in Clostridioides difficile infection
无菌粪便滤液在艰难梭菌感染中的疗效差异
Stefan Schreiber,Philip Rosenstiel,Stephan J Ott,Georg H Waetzig
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p94
6
Efficacy differentiation of sterile faecal filtrates in Clostridioides difficile infection – Authors’ reply
无菌粪便滤液在艰难梭菌感染中的疗效差异——作者回复
Dina Kao,Huiping Xu,Thomas Louie
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p94
7
Endoscopic palliation of malignant gastric outlet obstruction: harmonising outcomes
恶性胃出口梗阻的内镜下姑息治疗：统一疗效标准
Zachary L Smith
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p95
8
Clinical remission in ulcerative colitis: restoring precision in trial terminology
溃疡性结肠炎的临床缓解：恢复试验术语的精确性
Sailish Honap,Vipul Jairath,Fernando Magro,Silvio Danese,Laurent Peyrin-Biroulet
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p96
CORRECTIONS（更正）
9
Correction to Lancet Gastroenterol Hepatol 2019; 4: 364–75
对《柳叶刀-胃肠病学与肝病学》2019年；4卷：364-75页的更正
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：e1
10
Correction to Lancet Gastroenterol Hepatol 2025; 10: 431–41
对《柳叶刀-胃肠病学与肝病学》2025年；10卷：431-41页的更正
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：e1
NEWS（新闻）
11
Research in Brief
研究简讯
Holly Baker
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p98
IN FOCUS（焦点）
12
Patient Perspectives
患者视角
The label of a diagnosis
诊断标签
Cheryl Reeves
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p99
ARTICLES（论著）
13
Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial
Mirikizumab治疗中重度活动性溃疡性结肠炎儿童患者的疗效和安全性（SHINE-1）：一项多中心、开放标签、非随机2期试验
Jess L Kaplan,Athos Bousvaros,Dan Turner,Marla Dubinsky,Amy Larkin,Jordan Johns,Yuki Otani,Wallace Crandall,Wendy J Komocsar,Jeffrey S Hyams
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p100
14
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials
Glecirasib联合或不联合西妥昔单抗治疗既往接受过治疗的KRASG12C突变局部晚期或转移性结直肠癌（JAB-21822-1002和JAB-21822-1007）：两项开放标签、非随机1/2期试验
Jian Li,Zhenghang Wang,Jing Huang,Yi Ba,Baoshan Cao,Suxia Luo,Wenhua Li,Chunmei Bai,Zhengbo Song,Jianping Xiong,Liangjun Zhu,Guangyu An,Yanqiao Zhang,Zhihua Li,Yongsheng Li,Yanhong Gu,Changlu Hu,Xingya Li,Chenghui Huang,Qihan Fu,Xianli Yin,Xinjun Liang,Diansheng Zhong,Huaqiu Shi,Xiaoyan Li,Zhen Li,Lian Liu,Feng Wang,Rong Liang,Guohao Xia,Zhen Wang,Andrea Wang-Gillam,Yuli Ding,Zhiyue Rao,Wenhui Pan,Shuang Lu,Xin Sun,Lin Shen
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p110
15
Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial
卡瑞利珠单抗联合卡培他滨辅助治疗中国肝内胆管癌术后患者（ACC）：一项单臂、单中心、开放标签、2期试验
Zheng Wang,Lixing Li,Peiran Huang,Honghu Tu,Xiangyu Zhang,Lei Yu,Fei Liang,Cheng Huang,Shuangjian Qiu,Qinghai Ye,Zhenbin Ding,Xiaowu Huang,Yinghong Shi,Kang Song,Huichuan Sun,Xiaoying Wang,Yongfeng Xu,Yao Yu,Qiang Gao,Lan Zhang,Jia Fan,Jian Zhou
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p124
16
Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial
Tinengotinib治疗晚期或转移性胆管癌成人患者：一项多中心、开放标签、2期试验
Milind Javle,Christos Fountzilas,Chih-Yi Liao,Meredith Pelster,Daneng Li,Dustin Deming,Vaibhav Sahai,Lionel Kankeu Fonkoua,Allen Cohn,Parvez Mantry,Donald Richards,Edwin Kingsley,Frank Wu,Peng Peng,Katie Hennessy,Hui Wang,Caixia Sun,Shumao Ni,Jean Fan,Amit Mahipal
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p137
REVIEW（综述）
17
Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis
代谢功能障碍相关脂肪性肝炎当前及新兴治疗格局
Wenhao Li,William Alazawi,Rohit Loomba
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p150
VIEWPOINT（观点）
18
Ulcerative colitis: moving beyond the mucosal dogma
溃疡性结肠炎：超越黏膜教条
Elisabeth Eggermont,Krisztina Gecse,Noa Krugliak Cleveland,Frauke Petersen,João Sabino,AndréD'Hoore,Torsten Kucharzik,Mariangela Allocca,Gabriele Bislenghi,Kerri Novak,Gert De Hertogh,Christian Maaser,Bram Verstockt
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p163
THE LANCET Gastroenterology & Hepatology. Volume 11Number3
柳叶刀胃肠病学与肝病学 11卷 3期
https://www.thelancet.com/journals/langas/issue/current
EDITORIAL(社论)
1
Alcohol guidance in US dietary guidelines: a step backwards
美国膳食指南中的酒精建议：倒退的一步
The Lancet Gastroenterology & Hepatology
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p175
2
Thanks to our peer reviewers and contributors
感谢我们的同行评审专家和投稿者
The Lancet Gastroenterology & Hepatology
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p175
COMMENT（述评）
3
Appendicectomy: a disease-modifying treatment for ulcerative colitis?
阑尾切除术：溃疡性结肠炎的一种疾病修饰疗法？
Alexandra Damasio Todescatto,Paulo Gustavo Kotze
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p176
4
Cyclic exclusive enteral nutrition: a novel approach to maintaining remission in paediatric Crohn's disease
循环全肠内营养：维持儿童克罗恩病缓解的新方法
Anissa M Armet,Eytan Wine
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p177
5
Viral hepatitis in Roma communities: vulnerabilities and improving care access
罗姆人社区中的病毒性肝炎：易感性及改善医疗可及性
Pavol Kristian,Ivana Hockickova,Monika Halanova,Sylvia Drazilova,Ondrej Zahornacky,Peter Jarcuska
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p179
6
Thank you to The Lancet Gastroenterology & Hepatology's statistical and peer reviewers in 2025
感谢《柳叶刀 - 胃肠病学和肝病学》2025 年的统计学和同行评审专家
The Lancet Gastroenterology & Hepatology's Editors
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：e2
CORRESPONDENCE（读者来信）
7
Antipruritic effects of the ileal bile acid transporter inhibitor linerixibat
回肠胆汁酸转运体抑制剂利那西巴特的抗瘙痒作用
Gideon M Hirschfield,Andreas E Kremer,Cynthia Levy
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p182
8
Vedolizumab treatment outcomes in early versus late Crohn's disease
维多珠单抗治疗早期与晚期克罗恩病的疗效
Nurulamin M Noor,Ailsa L Hart,James C Lee,Miles Parkes
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p182
9
Vedolizumab treatment outcomes in early versus late Crohn's disease
维多珠单抗治疗早期与晚期克罗恩病的疗效
Rirong Chen,Kenneth Croitoru,Sun-Ho Lee
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p183
10
Vedolizumab treatment outcomes in early versus late Crohn's disease – Authors' reply
维多珠单抗治疗早期与晚期克罗恩病的疗效——作者回复
Geert R D'Haens,Lotte Oldenburg,Melanie S Hulshoffon behalf of the LOVE-CD collaborators
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p184
11
Global perspectives on sustainable IBD care
全球视角下的可持续炎症性肠病（IBD）诊疗
Olga M Nardone,Silvio Danese,Beatriz Gros,Tommaso L Parigion behalf of the Sustainable IBD Study Group
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p185
12
The impact of 2025 US NIDDK funding cuts
2025 年美国国家糖尿病、消化及肾脏疾病研究所（NIDDK）经费削减的影响
Rogelio Perez,Christopher W Chan,Aakash Reddy,David T Zhu
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p186
CORRECTIONS（更正）
13
Correction to Lancet Gastroenterol Hepatol 2026; 11: 34–45
对《柳叶刀 - 胃肠病学和肝病学》2026 年；11卷：34 - 45 页的更正
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：e5
14
Correction to Lancet Gastroenterol Hepatol 2026; 11: 89–91
对《柳叶刀 - 胃肠病学和肝病学》2026 年；11卷：89 - 91 页的更正
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：e5
NEWS（新闻）
15
ASCO Gastrointestinal Cancers Symposium 2026
2026 年美国临床肿瘤学会（ASCO）胃肠道肿瘤研讨会
Rob Brierley
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p188
IN FOCUS（焦点）
Book（书籍）
16
Stoma: life saver, not a barrier
造口：救命手段，而非障碍
Lucy Mae Spurgeon
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p189
ARTICLES（论著）
17
Appendicectomy versus switching to a JAK inhibitor in inducing remission in patients with active ulcerative colitis after biologic therapy failure (COSTA): 1-year results of a multicentre, prospective, cohort study
生物制剂治疗失败后，阑尾切除术与换用 JAK 抑制剂诱导活动期溃疡性结肠炎患者缓解的对比（COSTA）：一项多中心、前瞻性、队列研究的 1 年结果
Eva Visser,Maud A Reijntjes,Lianne Heuthorst,Merle E Stellingwerf,Rachel West,Koen van Dongen,Rogier M P H Crolla,Susan van Dieren,Jarmila D W van der Bilt,Willem A Bemelman,Geert R D'Haens,Christianne J Buskensfor the COSTA Study Group
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p190
18
Cyclic exclusive enteral nutrition versus partial enteral nutrition to maintain long-term drug-free remission in paediatric Crohn's disease (CD-HOPE): an open-label, endpoint-blinded, randomised controlled trial
循环全肠内营养与部分肠内营养维持儿童克罗恩病长期无药物缓解的对比（CD - HOPE）：一项开放标签、终点盲法、随机对照试验
Bénédicte Pigneur,Christine Martinez-Vinson,Aurélie Bourmaud,Alain Dabadie,Rémi Duclaux-Loras,Jean-Pierre Hugot,Céline Roman,Clémentine Dumant,Claire Spyckerelle,Vincent Guinard-Samuel,Stéphanie Willot,Claire Dupont,Anne Breton,Nicolas Caron,Emilie Chaillou,Laurent Rebouissoux,Valérie Bertrand,Valérie Triolo,Justine Pages,Djamal Djeddi,Marjorie Bonneton,Stéphanie Uhlen,Natacha Catteau,Stéphanie Coopman,Patricia Lepage,Jérôme Viala,Frank M Ruemmele
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p204
19
ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial
ALG - 000184（佩维福司科韦钠）单药治疗慢性乙型肝炎病毒感染者：一项 1 期、多中心、随机、剂量递增试验
Man-Fung Yuen,Kosh Agarwal,Alina Jucov,Jinlin Hou,Junqi Niu,Yanhua Ding,Alexei Haceatrean,Xie'er Liang,Jia Xu,Min Wu,Kha Le,Tse-I Lin,Lawrence Blatt,Sushmita Chanda,John Fry,Ed Gane
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p218
20
Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study
代谢功能障碍相关脂肪性肝病和代谢功能障碍相关脂肪性肝炎的最佳干预措施：一项全球德尔菲研究
Jeffrey V Lazarus,Leire Agirre-Garrido,Trenton M White,Anish K Arora,Melina I Manolas,Luis Antonio Diaz,Juan Pablo Arab,Shira Zelber-Sagi,Naim Alkhouri,C Wendy Spearman,Jörn M Schattenberg,Loreta A Kondili,Patrizia Carrieri,Holly F Lofton,Priya Jaisinghani,Sonal Kumar,Ajay Duseja,Mohamed El-Kassas,Hirokazu Takahasi,Debbie L Shawcross,Jonathan G Stine,Marcela Villota-Rivas,Juan Emilio Miralles-Sanchez,Silvana Pannain,Paul N BrennanMASLD/MASH Collaborators
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p232
REVIEW（综述）
21
Definitions, diagnosis, management, and outcomes of upper gastrointestinal Crohn's disease: an international, expert RAND/UCLA appropriateness study
上消化道克罗恩病的定义、诊断、治疗和转归：一项国际专家兰德/加州大学洛杉矶分校适用性研究
Nathaniel A Cohen,Dominik Bettenworth,Neta Sror,Raneem Khedraki,Qijun Yang,Maria T Abreu,Raja Atreya,Badr Al-Bawardy,Susan J Connor,Geert D'Haens,Iris Dotan,Axel Dignass,Sara El Ouali,Brian Feagan,Roger Feakins,Richard Gearry,Ilyssa O Gordon,Charlotte R H Hedin,Cristian Hernandez-Rocha,Taku Kobayashi,Haim Leibovitzh,Cathy Lu,Nitsan Maharshak,Maliha Naseer,Jacob Ollech,David T Rubin,Shaji Sebastian,Britta Siegmund,Mark S Silverberg,Flavio Steinwurz,Joana Torres,Gill Watermeyer,Tina Aswani Omprakash,Lior Frenkel,Paige Gurizzian,Alexa Silfen,Roie Tzadok,Katherine Falloon,Florian Riederon behalf of the Study of Upper Gastrointestinal Manifestations and Management of Crohn's Disease (SUMM-CD) Group
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p243
22
Mechanisms and pathophysiology leading to development of small intestinal microbial dysbiosis
导致小肠微生物群失调的机制和病理生理学
John A Damianos,Xiao Jing Wang,Michael Camilleri
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p256
THE LANCET Gastroenterology & Hepatology. Volume 11Number4
柳叶刀胃肠病学与肝病学 11卷 4期
https://www.thelancet.com/journals/langas/issue/current
Editorial（社论）
1
Preventive cholera vaccination resumes
预防性霍乱疫苗接种重新启动
The Lancet Gastroenterology & Hepatology
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p267
2
Putting steatotic liver disease on the global NCD agenda
将脂肪变性肝病纳入全球非传染性疾病议程
The Lancet Gastroenterology & Hepatology
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p267
Comment（述评）
3
Menopause and inflammatory bowel disease: more questions than answers
绝经与炎症性肠病：疑问多于答案
Samantha Conley,Kendra J Kamp,Sunanda V Kane
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p268
4
Voices from the frontline: how global funding cuts are reshaping the viral hepatitis response
前线之声：全球资金削减如何重塑病毒性肝炎应对策略
Marion Delphin,Monica Fambrough,Jana Manning,Lindsey Hiebert-Suwondo,Jessica Hicks,Philippa C Matthews
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p269
5
Delivering therapeutic diets for gastrointestinal disease to people with intellectual disabilities
为患有胃肠道疾病的智力障碍人群提供治疗性饮食
Lynette Harper,Ian H Walshe,Leigh Donnelly
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p271
6
Making room under the umbrella for microscopic colitis
在伞状范畴下为显微镜下结肠炎留出一席之地
Jillian Horton,Edward V Loftus Jr
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p274
Correspondence（读者来信）
7
The evolving clinical trial landscape in the MENA region
中东和北非地区临床试验格局的演变
Mohammed Nabil Quraishi,Badr Al-Bawardy
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p277
8
The evolving clinical trial landscape in the MENA region
中东和北非地区临床试验格局的演变
Yasser Fouad,Abdulla Al Hassani,Nawal Alkhalidi,Faisal Abaalkhail,Mohammed Eslam
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p278
9
Difficulties in identifying a signal of activity in the adjuvant setting for biliary tract cancer
在胆道癌辅助治疗中识别活性信号的困难
Julien Edeline,John Bridgewater
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p278
10
Difficulties in identifying a signal of activity in the adjuvant setting for biliary tract cancer – Authors' reply
在胆道癌辅助治疗中识别活性信号的困难——作者回复
Lixing Li,Fei Liang,Zheng Wang,Jia Fan,Jian Zhouon behalf of the ACC investigators
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p279
11
Developing policy for steatotic liver disease: an even better buy?
制定脂肪变性肝病政策：更划算的选择？
Oliver D Tavabie,Megan E Rawcliffe,Mads Israelsen
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p280
Corrections（更正）
12
Correction to Lancet Gastroenterol Hepatol 2025; 10: 634–47
《柳叶刀-胃肠病学与肝病学》2025年；第10卷：第634 - 47页勘误
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：e6
13
Correction to Lancet Gastroenterol Hepatol 2026; 11: 22–33
《柳叶刀-胃肠病学与肝病学》2026年；第11卷：第22 - 33页勘误
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：e6
News（新闻）
14
ECCO 2026
2026年欧洲克罗恩病和结肠炎组织会议
Rob Brierley
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p281
15
Research in Brief
研究简讯
Holly Baker
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p282
In Focus（焦点）
16
Food Matters
食品问题
Low-carbohydrate diets—how low can we go?
低碳水化合物饮食——我们能低到什么程度？
Sanna Nybacka,Heidi M Staudacher
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p283
Articles（论著）
17
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial
皮下古塞库单抗诱导治疗中重度活动性溃疡性结肠炎受试者的有效性和安全性（ASTRO研究）：一项双盲、全程治疗、随机、安慰剂对照的3期试验
Millie Long,Jessica R Allegretti,Silvio Danese,Matthew Germinaro,Thomas Baker,Yelina Alvarez,Mary Kavalam,Chenglong Han,Silke Jörgens,Lingjing Jiang,Hongyan Zhang,Tadakazu Hisamatsu,David T Rubin,Laurent Peyrin-Birouleton behalf of the ASTRO Study Group
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p284
18
Safety, pharmacokinetics, and preliminary efficacy of VS-01, an intraperitoneal liposomal infusion, in patients with decompensated liver cirrhosis, ascites, and covert hepatic encephalopathy: a phase 1b, first-in-human, open-label, non-randomised, single ascending and multiple dose study
VS - 01（一种腹腔内脂质体输注液）在失代偿期肝硬化、腹水和隐性肝性脑病患者中的安全性、药代动力学和初步疗效：一项1b期、首次人体、开放标签、非随机、单次递增和多次给药研究
Frank Erhard Uschner,Martin McCoy,Olaf Tyc,Wenyi Gu,Philip Ferstl,Maximilian Joseph Brol,Johannes Masseli,Kai-Henrik Peiffer,Fabian Finkelmeier,Stefan Zeuzem,Sophie Biguenet,Katharina Staufer,Meriam Kabbaj,Jonel Trebicka
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p299
19
Ileocaecal resection versus infliximab for ileal Crohn's disease: retrospective 10-year follow-up of the LIR!C trial
回盲部切除术与英夫利昔单抗治疗回肠克罗恩病：LIR!C试验的10年回顾性随访
Lotte Oldenburg,Anouck E G Haanappel,Mahsoem Ali,Carolijn Bosman,Christianne J Buskens,Cyriel Y Ponsioen,Geert R D'Haens,Willem A Bemelmanon behalf of the LIR!C study group
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p314
20
Long-term oncological outcomes following algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection: a post-hoc analysis of a nationwide, stepped-wedge cluster-randomised trial
基于算法的护理与常规护理对胰腺切除术后并发症早期识别和治疗的长期肿瘤学预后：一项全国性、阶梯楔形整群随机试验的事后分析
Thijs J Schouten,Kyra J Prinsze,Anne Claire Henry,Lois A Daamen,Marc G Besselink,Bert A Bonsing,Koop Bosscha,Olivier R Busch,Geert A Cirkel,Ronald M van Dam,Casper H van Eijck,Sebastiaan Festen,Bas Groot Koerkamp,Erwin van der Harst,Ignace H J T de Hingh,Geert Kazemier,Mike S L Liem,Vincent E de Meijer,J Sven D Mieog,Gijs A Patijn,Daphne Roos,Jennifer M J Schreinemakers,Martijn W J Stommel,Fennie Wit,C Henri van Werkhoven,I Quintus Molenaar,F Jasmijn Smits,Hjalmar C van Santvoortfor the Dutch Pancreatic Cancer Group
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p323
Review（综述）
21
Chronic liver disease and hepatology care in transgender and gender diverse populations
跨性别者和性别多元人群的慢性肝病和肝病学护理
Thanh N Nguyen,Whitney E Jackson,Nitzan C Roth,Felice Cinque,Monika Sarkar,Niharika Samala,Rita S Lee,Alexandra T Strauss,Jessica Wisocky,Keyur Patel,Giada Sebastiani,Carl G Streed Jr,Jordan E Lake,Tzu-Hao Lee
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p334
THE LANCET Gastroenterology & Hepatology. Volume 11Number5
柳叶刀·胃肠病学与肝病学 11卷 5期
https://www.thelancet.com/journals/langas/issue/current
EDITORIAL(社论)
1
Early-onset colorectal cancer: rising rates require rising awareness
早发性结直肠癌：发病率上升需提高认知
The Lancet Gastroenterology & Hepatology
The Lancet Gastroenterology & Hepatology. May 2026, Vol 11(5)：p345
COMMENT（述评）
2
Transanal total mesorectal excision in the era of robotic surgery
机器人手术时代的经肛全直肠系膜切除术
Patricia Sylla
The Lancet Gastroenterology & Hepatology. May 2026, Vol 11(5)：p346
3
Indocyanine green works: redefining research priorities in colorectal surgery
吲哚菁绿起效：重新定义结直肠外科研究重点
Zoe Garoufalia
The Lancet Gastroenterology & Hepatology. May 2026, Vol 11(5)：p347
4
Africa must not be left out of the hepatitis B cure era
非洲不能被排除在乙肝治愈时代之外
Mohamed El-Kassas,Hend Shousha,Asgeir Johannessenon behalf of the Hepatitis B in Africa Collaborative Network (HEPSANET)
The Lancet Gastroenterology & Hepatology. May 2026, Vol 11(5)：p349
5
Global gains, metabolic pains: unmasking the hidden burden on liver health
全球获益，代谢之痛：揭开肝脏健康隐性负担的面纱
Maja Thiele,Ajeet Singh Bhadoria,Jessica Mellinger,Shira Zelber-Sagi,Pinelopi Manousou,Debbie L Shawcross,Neeraj Bhala
The Lancet Gastroenterology & Hepatology. May 2026, Vol 11(5)：p351
CORRECTIONS（更正）
6
Correction to Lancet Gastroenterol Hepatol 2022; 7: 202–03
对《柳叶刀·胃肠病学和肝病学》2022年；第7卷：202 - 03的勘误
The Lancet Gastroenterology & Hepatology. May 2026, Vol 11(5)：e7
7
Correction to Lancet Gastroenterol Hepatol 2024; 9: 1041–51
对《柳叶刀·胃肠病学和肝病学》2024年；第9卷：1041 - 51的勘误
The Lancet Gastroenterology & Hepatology. May 2026, Vol 11(5)：e7
IN FOCUS（焦点）
Film（电影）
8
André is an Idiot
《安德烈是个白痴》
Joe Moody
The Lancet Gastroenterology & Hepatology. May 2026, Vol 11(5)：p354
ARTICLES（论著）
9
Transanal total mesorectal excision versus laparoscopic total mesorectal excision for mid and low rectal cancer (COLOR III): short-term outcomes of an international, multicentre, phase 3, randomised, controlled, non-inferiority trial
经肛全直肠系膜切除术与腹腔镜全直肠系膜切除术治疗中低位直肠癌（COLOR III）：一项国际多中心3期随机对照非劣效性试验的短期结果
Jurriaan B Tuynman,Hongwei Yao,Laura R Moolenaar,Colin Sietses,Roel Hompes,Felix Aigner,Antonio Caycedo–Marulanda,Chien-Chih Chen,Muneer Deeb,Pascal G Doornebosch,Bo Feng,Chi-Chung Foo,Alois Fürst,Masaaki Ito,Francisco B de Lacy,Pedro Leão,Justin A Maykel,Andrea Muratore,Stefan E van Oostendorp,Sung Chan Park,MichałPędziwiatr,MingYang Ren,Gerald Seitinger,Hein B A C Stockmann,Aaldert K Talsma,Andreas Türler,Weidong Tong,Quan Wang,Qing Xu,Hongyu Zhang,Jan-Hein T M van Waesberghe,Mahsoem Ali,Jos W R Twisk,Zhongtao Zhang,Antonio M de Lacy,George B Hanna,Hendrik J Bonjeron behalf of the COLOR III Study Group
The Lancet Gastroenterology & Hepatology. May 2026, Vol 11(5)：p355
10
Indocyanine green fluorescence angiography for anastomotic perfusion assessment in colorectal surgery: a systematic review with meta-analysis, meta-regression, and trial sequential analyses
吲哚菁绿荧光血管造影用于结直肠手术吻合口灌注评估：一项包含荟萃分析、荟萃回归分析和试验序贯分析的系统综述
Éanna J Ryan,Odhrán K Ryan,Neil Corrigan,Gemma Ainsworth,Denise E Hilling,Alexander L Vahrmeijer,Jyrki Kössi,Jun Watanabe,David Jayne,Ronan A Cahill
The Lancet Gastroenterology & Hepatology. May 2026, Vol 11(5)：p367
11
Natural history of chronic hepatitis B in untreated adults without cirrhosis according to baseline hepatitis B virus DNA and alanine aminotransferase concentrations: a systematic review and meta-analysis
根据基线乙肝病毒DNA和丙氨酸氨基转移酶浓度，未接受治疗的无肝硬化成年慢性乙肝患者的自然病程：一项系统综述和荟萃分析
Daniela Yucuma,Arthur Rakover,Zakary Ismail Warsop,Yu Ri Im,Si Emma Chen,Rukmini Jagdish,Gibril Ndow,Maud Lemoine,Hailemichael Desalegn,Asgeir Johannessen,Hwai-I Yang,Yasuhito Tanaka,Roger Chou,Philippa Easterbrook,Yusuke Shimakawa
The Lancet Gastroenterology & Hepatology. May 2026, Vol 11(5)：p380
12
Efficacy of antiviral therapy in adults with chronic hepatitis B according to baseline hepatitis B virus DNA and alanine aminotransferase concentrations: a systematic review and meta-analysis
根据基线乙肝病毒DNA和丙氨酸氨基转移酶浓度，慢性乙肝成年患者抗病毒治疗的疗效：一项系统综述和荟萃分析
Yu Ri Im,Si Emma Chen,Rukmini Jagdish,Daniela Yucuma,Arthur Rakover,Zakary Ismail Warsop,Roger Chou,Philippa Easterbrook,Yusuke Shimakawa
The Lancet Gastroenterology & Hepatology. May 2026, Vol 11(5)：p397
REVIEW（综述）
13
Who to test and reflex testing for hepatitis D virus infection: evidence and rationale to inform policy recommendations and future directions
丁型肝炎病毒感染的检测对象及复检策略：为政策建议和未来方向提供依据与理论支撑
Sahar Bajis,Niklas Luhmann,Emi Okamoto,Robia Islam,Olufunmilayo Lesi,Philippa Easterbrook
The Lancet Gastroenterology & Hepatology. May 2026, Vol 11(5)：p417
14
How to test for hepatitis D virus infection: evidence and rationale to inform policy recommendations and future directions
如何检测丁型肝炎病毒感染：为制定政策建议和未来方向提供证据和依据
Emi E Okamoto,Robia Islam,Sahar Bajis,Niklas Luhmann,Ashley Kallarakal,Frédéric Le Gal,Philippa Easterbrook
The Lancet Gastroenterology & Hepatology. May 2026, Vol 11(5)：p426
临床3期临床2期临床结果
2026-04-20
THE LANCET Gastroenterology & Hepatology. Volume 11Number1
柳叶刀胃肠病学与肝病学 11卷 1期
https://www.thelancet.com/journals/langas/issue/current
EDITORIAL(社论)
1
Accelerating MASH trials: from biopsy to biomarkers
加速MASH（代谢障碍相关脂肪性肝炎）试验：从活检到生物标志物
The Lancet Gastroenterology & Hepatology
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p1
COMMENT（述评）
2
Optimising treatment in Crohn's disease: is the main issue early versus late or biologic naive versus biologic experienced?
优化克罗恩病的治疗：主要问题在于早期治疗与晚期治疗，还是生物制剂初治患者与生物制剂经治患者？
Marte Lie Høivik
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p2
3
Ileal bile acid transporter inhibitors for cholestatic pruritus in primary biliary cholangitis
针对原发性胆汁性胆管炎中胆汁淤积性瘙痒的回肠胆汁酸转运蛋白抑制剂
Ansgar W Lohse,David N Assis
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p3
4
Dual targeting of TNF and IL-23 by a bispecific antibody in ulcerative colitis
双特异性抗体在溃疡性结肠炎中同时靶向TNF和IL-23
Raja Atreya,Markus F Neurath
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p5
5
The essential medicines list for inflammatory bowel disease: time to raise the standards of global care
炎症性肠病基本药物清单：是时候提高全球护理标准了
Nanne K de Boer,Richard B Gearry,Charles N Bernstein,Rupa Banerjee,David T Rubin,Gilaad G Kaplanon behalf of the Globalization Cluster of the International Organization of IBD
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p7
NEWS（新闻）
6
The Liver Meeting 2025
2025年肝脏会议
Rob Brierley
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p10
IN FOCUS（焦点）
7
Food Matters
食物很重要
Dietary management of constipation: time for clinical guidelines to catch up with evidence
便秘的饮食治疗：是时候让临床指南跟上证据的步伐了
Eirini Dimidi,Kevin Whelan
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p11
ARTICLES（论著）
8
Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study
维多珠单抗在早期和晚期克罗恩病中的应用（LOVE-CD）：一项4期开放性队列研究
Geert R D'Haens,Mark Löwenberg,Filip Baert,Peter Bossuyt,Tamás Molnár,Frank Hoentjen,Esmé Clasquin,Krisztina B Gecse,Melanie S Hulshoff,Gert De Hertogh,Matthias Lenfant,Lotte Oldenburg,Séverine Vermeire
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p12
9
Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): 利尼西巴特治疗原发性胆汁性胆管炎和胆汁淤积性瘙痒患者（GLISTEN）：一项随机、多中心、双盲、安慰剂对照的3期试验
a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
Gideon M Hirschfield,Christopher L Bowlus,David E J Jones,Andreas E Kremer,Marlyn J Mayo,Atsushi Tanaka,Pietro Andreone,Jidong Jia,Qinglong Jin,Ricardo U Macías-Rodríguez,Alexander R Cobitz,Brooke M Currie,Ciara Gorey,Ivana Lazic,Danielle Podmore,Andrea Ribeiro,Jennifer B Shannon,Brandon Swift,Megan M McLaughlin,Cynthia Levyfor the GLISTEN Study Group
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p22
10
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial
SOR102（一种口服双特异性肿瘤坏死因子和白细胞介素-23抑制剂）在健康受试者和溃疡性结肠炎患者中的安全性和药代动力学：一项首次人体、双盲、随机、安慰剂对照的1期试验
Vipul Jairath,Silvio Danese,Geert R D’Haens,Brian G Feagan,Laurent Peyrin-Biroulet,Bruce E Sands,Ingrid Gaemers,Matt Westfall,Allyson Q Terry,Kevin J Roberts,Sara Barbat,Pamela Wedel,Jacqueline M Benson,Carlos Sattler
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p34
11
Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial
西洛芬酸在非肝硬化原发性硬化性胆管炎中的应用（PRIMIS）：一项随机、双盲、多中心、安慰剂对照的3期试验
Michael Trauner,Cynthia Levy,Atsushi Tanaka,Zachary Goodman,Douglas Thorburn,Deepak Joshi,Kimmo Salminen,Kidist Yimam,Hiroyuki Isayama,Aldo J Montano-Loza,Stephen Caldwell,Mark Danta,Martti Farkkila,Juan F Gallegos-Orozco,Stuart C Gordon,Holger Hinrichsen,Pietro Invernizzi,Raj Vuppalanchi,Kaiyi Zhu,Jun Xu,Xiangyu Liu,Xiaomin Lu,Gerald Crans,Shahla Bolbolan,Lisa Boyette,Muhsen Alani,William T Barchuk,Timothy R Watkins,Mark C Genovese,Christopher L Bowlus
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p46
REVIEW（综述）
12
Age-related changes of the gastrointestinal tract
胃肠道的年龄相关变化
Alberto Pilotto,Carlo Custodero,Lucilla Crudele,Wanda Morganti,Nicola Veronese,Marilisa Franceschi
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p59
13
Fatigue in people with primary biliary cholangitis: a position paper from the European Reference Network for Rare Liver Diseases
原发性胆汁性胆管炎患者的疲劳问题：欧洲罕见肝病参考网络立场文件
Ozgur M Koc,Anne-Kristin Toussaint,Aurelie Untas,Piotr Milkiewicz,Henriette Ytting,Laura Buck,David E Jones,Gideon Hirschfield,Angela Leburgue,Christoph Schramm,Frederik Nevens,Adriaan J van der Meer,Alessio Gerussi,Jef Verbeek
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p71
THE LANCET Gastroenterology & Hepatology. Volume 11Number2
柳叶刀胃肠病学与肝病学 11卷 2期
https://www.thelancet.com/journals/langas/issue/current
EDITORIAL(社论)
1
ACIP's HBV birth-dose vaccine recommendations: a fiasco
美国免疫接种咨询委员会（ACIP）的乙肝疫苗出生剂量推荐：一场闹剧
The Lancet Gastroenterology & Hepatology
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p87
COMMENT（述评）
2
Expanding the therapeutic arsenal for paediatric ulcerative colitis
扩充儿童溃疡性结肠炎的治疗武器库
Stephanie A Vuijk,Esmée H Boute,Lissy de Ridder
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p88
3
Closing the Middle East and north Africa representation gap in clinical trials in inflammatory bowel disease
缩小炎症性肠病临床试验中中东和北非地区代表不足的差距
Mohammad Shebab,Ahmed Al-Hindawi,Shane W Goodwin,Yuhong Yuan,Talat Bessissow,Laurent Peyrin-Biroulet,Vipul Jairath
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p89
4
Colorectal cancer screening in LGBTQIA+ people: an urgent call for equity
对LGBTQIA+人群进行结直肠癌筛查：迫切呼吁公平
Vidhi Singh,Jayraan Badiee,Alexander Goldowsky,David Russo,Folasade P May
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p91
CORRESPONDENCE（读者来信）
5
Efficacy differentiation of sterile faecal filtrates in Clostridioides difficile infection
无菌粪便滤液在艰难梭菌感染中的疗效差异
Stefan Schreiber,Philip Rosenstiel,Stephan J Ott,Georg H Waetzig
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p94
6
Efficacy differentiation of sterile faecal filtrates in Clostridioides difficile infection – Authors’ reply
无菌粪便滤液在艰难梭菌感染中的疗效差异——作者回复
Dina Kao,Huiping Xu,Thomas Louie
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p94
7
Endoscopic palliation of malignant gastric outlet obstruction: harmonising outcomes
恶性胃出口梗阻的内镜下姑息治疗：统一疗效标准
Zachary L Smith
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p95
8
Clinical remission in ulcerative colitis: restoring precision in trial terminology
溃疡性结肠炎的临床缓解：恢复试验术语的精确性
Sailish Honap,Vipul Jairath,Fernando Magro,Silvio Danese,Laurent Peyrin-Biroulet
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p96
CORRECTIONS（更正）
9
Correction to Lancet Gastroenterol Hepatol 2019; 4: 364–75
对《柳叶刀-胃肠病学与肝病学》2019年；4卷：364-75页的更正
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：e1
10
Correction to Lancet Gastroenterol Hepatol 2025; 10: 431–41
对《柳叶刀-胃肠病学与肝病学》2025年；10卷：431-41页的更正
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：e1
NEWS（新闻）
11
Research in Brief
研究简讯
Holly Baker
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p98
IN FOCUS（焦点）
12
Patient Perspectives
患者视角
The label of a diagnosis
诊断标签
Cheryl Reeves
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p99
ARTICLES（论著）
13
Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial
Mirikizumab治疗中重度活动性溃疡性结肠炎儿童患者的疗效和安全性（SHINE-1）：一项多中心、开放标签、非随机2期试验
Jess L Kaplan,Athos Bousvaros,Dan Turner,Marla Dubinsky,Amy Larkin,Jordan Johns,Yuki Otani,Wallace Crandall,Wendy J Komocsar,Jeffrey S Hyams
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p100
14
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials
Glecirasib联合或不联合西妥昔单抗治疗既往接受过治疗的KRASG12C突变局部晚期或转移性结直肠癌（JAB-21822-1002和JAB-21822-1007）：两项开放标签、非随机1/2期试验
Jian Li,Zhenghang Wang,Jing Huang,Yi Ba,Baoshan Cao,Suxia Luo,Wenhua Li,Chunmei Bai,Zhengbo Song,Jianping Xiong,Liangjun Zhu,Guangyu An,Yanqiao Zhang,Zhihua Li,Yongsheng Li,Yanhong Gu,Changlu Hu,Xingya Li,Chenghui Huang,Qihan Fu,Xianli Yin,Xinjun Liang,Diansheng Zhong,Huaqiu Shi,Xiaoyan Li,Zhen Li,Lian Liu,Feng Wang,Rong Liang,Guohao Xia,Zhen Wang,Andrea Wang-Gillam,Yuli Ding,Zhiyue Rao,Wenhui Pan,Shuang Lu,Xin Sun,Lin Shen
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p110
15
Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial
卡瑞利珠单抗联合卡培他滨辅助治疗中国肝内胆管癌术后患者（ACC）：一项单臂、单中心、开放标签、2期试验
Zheng Wang,Lixing Li,Peiran Huang,Honghu Tu,Xiangyu Zhang,Lei Yu,Fei Liang,Cheng Huang,Shuangjian Qiu,Qinghai Ye,Zhenbin Ding,Xiaowu Huang,Yinghong Shi,Kang Song,Huichuan Sun,Xiaoying Wang,Yongfeng Xu,Yao Yu,Qiang Gao,Lan Zhang,Jia Fan,Jian Zhou
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p124
16
Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial
Tinengotinib治疗晚期或转移性胆管癌成人患者：一项多中心、开放标签、2期试验
Milind Javle,Christos Fountzilas,Chih-Yi Liao,Meredith Pelster,Daneng Li,Dustin Deming,Vaibhav Sahai,Lionel Kankeu Fonkoua,Allen Cohn,Parvez Mantry,Donald Richards,Edwin Kingsley,Frank Wu,Peng Peng,Katie Hennessy,Hui Wang,Caixia Sun,Shumao Ni,Jean Fan,Amit Mahipal
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p137
REVIEW（综述）
17
Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis
代谢功能障碍相关脂肪性肝炎当前及新兴治疗格局
Wenhao Li,William Alazawi,Rohit Loomba
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p150
VIEWPOINT（观点）
18
Ulcerative colitis: moving beyond the mucosal dogma
溃疡性结肠炎：超越黏膜教条
Elisabeth Eggermont,Krisztina Gecse,Noa Krugliak Cleveland,Frauke Petersen,João Sabino,AndréD'Hoore,Torsten Kucharzik,Mariangela Allocca,Gabriele Bislenghi,Kerri Novak,Gert De Hertogh,Christian Maaser,Bram Verstockt
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p163
THE LANCET Gastroenterology & Hepatology. Volume 11Number3
柳叶刀胃肠病学与肝病学 11卷 3期
https://www.thelancet.com/journals/langas/issue/current
EDITORIAL(社论)
1
Alcohol guidance in US dietary guidelines: a step backwards
美国膳食指南中的酒精建议：倒退的一步
The Lancet Gastroenterology & Hepatology
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p175
2
Thanks to our peer reviewers and contributors
感谢我们的同行评审专家和投稿者
The Lancet Gastroenterology & Hepatology
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p175
COMMENT（述评）
3
Appendicectomy: a disease-modifying treatment for ulcerative colitis?
阑尾切除术：溃疡性结肠炎的一种疾病修饰疗法？
Alexandra Damasio Todescatto,Paulo Gustavo Kotze
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p176
4
Cyclic exclusive enteral nutrition: a novel approach to maintaining remission in paediatric Crohn's disease
循环全肠内营养：维持儿童克罗恩病缓解的新方法
Anissa M Armet,Eytan Wine
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p177
5
Viral hepatitis in Roma communities: vulnerabilities and improving care access
罗姆人社区中的病毒性肝炎：易感性及改善医疗可及性
Pavol Kristian,Ivana Hockickova,Monika Halanova,Sylvia Drazilova,Ondrej Zahornacky,Peter Jarcuska
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p179
6
Thank you to The Lancet Gastroenterology & Hepatology's statistical and peer reviewers in 2025
感谢《柳叶刀 - 胃肠病学和肝病学》2025 年的统计学和同行评审专家
The Lancet Gastroenterology & Hepatology's Editors
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：e2
CORRESPONDENCE（读者来信）
7
Antipruritic effects of the ileal bile acid transporter inhibitor linerixibat
回肠胆汁酸转运体抑制剂利那西巴特的抗瘙痒作用
Gideon M Hirschfield,Andreas E Kremer,Cynthia Levy
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p182
8
Vedolizumab treatment outcomes in early versus late Crohn's disease
维多珠单抗治疗早期与晚期克罗恩病的疗效
Nurulamin M Noor,Ailsa L Hart,James C Lee,Miles Parkes
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p182
9
Vedolizumab treatment outcomes in early versus late Crohn's disease
维多珠单抗治疗早期与晚期克罗恩病的疗效
Rirong Chen,Kenneth Croitoru,Sun-Ho Lee
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p183
10
Vedolizumab treatment outcomes in early versus late Crohn's disease – Authors' reply
维多珠单抗治疗早期与晚期克罗恩病的疗效——作者回复
Geert R D'Haens,Lotte Oldenburg,Melanie S Hulshoffon behalf of the LOVE-CD collaborators
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p184
11
Global perspectives on sustainable IBD care
全球视角下的可持续炎症性肠病（IBD）诊疗
Olga M Nardone,Silvio Danese,Beatriz Gros,Tommaso L Parigion behalf of the Sustainable IBD Study Group
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p185
12
The impact of 2025 US NIDDK funding cuts
2025 年美国国家糖尿病、消化及肾脏疾病研究所（NIDDK）经费削减的影响
Rogelio Perez,Christopher W Chan,Aakash Reddy,David T Zhu
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p186
CORRECTIONS（更正）
13
Correction to Lancet Gastroenterol Hepatol 2026; 11: 34–45
对《柳叶刀 - 胃肠病学和肝病学》2026 年；11卷：34 - 45 页的更正
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：e5
14
Correction to Lancet Gastroenterol Hepatol 2026; 11: 89–91
对《柳叶刀 - 胃肠病学和肝病学》2026 年；11卷：89 - 91 页的更正
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：e5
NEWS（新闻）
15
ASCO Gastrointestinal Cancers Symposium 2026
2026 年美国临床肿瘤学会（ASCO）胃肠道肿瘤研讨会
Rob Brierley
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p188
IN FOCUS（焦点）
Book（书籍）
16
Stoma: life saver, not a barrier
造口：救命手段，而非障碍
Lucy Mae Spurgeon
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p189
ARTICLES（论著）
17
Appendicectomy versus switching to a JAK inhibitor in inducing remission in patients with active ulcerative colitis after biologic therapy failure (COSTA): 1-year results of a multicentre, prospective, cohort study
生物制剂治疗失败后，阑尾切除术与换用 JAK 抑制剂诱导活动期溃疡性结肠炎患者缓解的对比（COSTA）：一项多中心、前瞻性、队列研究的 1 年结果
Eva Visser,Maud A Reijntjes,Lianne Heuthorst,Merle E Stellingwerf,Rachel West,Koen van Dongen,Rogier M P H Crolla,Susan van Dieren,Jarmila D W van der Bilt,Willem A Bemelman,Geert R D'Haens,Christianne J Buskensfor the COSTA Study Group
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p190
18
Cyclic exclusive enteral nutrition versus partial enteral nutrition to maintain long-term drug-free remission in paediatric Crohn's disease (CD-HOPE): an open-label, endpoint-blinded, randomised controlled trial
循环全肠内营养与部分肠内营养维持儿童克罗恩病长期无药物缓解的对比（CD - HOPE）：一项开放标签、终点盲法、随机对照试验
Bénédicte Pigneur,Christine Martinez-Vinson,Aurélie Bourmaud,Alain Dabadie,Rémi Duclaux-Loras,Jean-Pierre Hugot,Céline Roman,Clémentine Dumant,Claire Spyckerelle,Vincent Guinard-Samuel,Stéphanie Willot,Claire Dupont,Anne Breton,Nicolas Caron,Emilie Chaillou,Laurent Rebouissoux,Valérie Bertrand,Valérie Triolo,Justine Pages,Djamal Djeddi,Marjorie Bonneton,Stéphanie Uhlen,Natacha Catteau,Stéphanie Coopman,Patricia Lepage,Jérôme Viala,Frank M Ruemmele
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p204
19
ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial
ALG - 000184（佩维福司科韦钠）单药治疗慢性乙型肝炎病毒感染者：一项 1 期、多中心、随机、剂量递增试验
Man-Fung Yuen,Kosh Agarwal,Alina Jucov,Jinlin Hou,Junqi Niu,Yanhua Ding,Alexei Haceatrean,Xie'er Liang,Jia Xu,Min Wu,Kha Le,Tse-I Lin,Lawrence Blatt,Sushmita Chanda,John Fry,Ed Gane
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p218
20
Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study
代谢功能障碍相关脂肪性肝病和代谢功能障碍相关脂肪性肝炎的最佳干预措施：一项全球德尔菲研究
Jeffrey V Lazarus,Leire Agirre-Garrido,Trenton M White,Anish K Arora,Melina I Manolas,Luis Antonio Diaz,Juan Pablo Arab,Shira Zelber-Sagi,Naim Alkhouri,C Wendy Spearman,Jörn M Schattenberg,Loreta A Kondili,Patrizia Carrieri,Holly F Lofton,Priya Jaisinghani,Sonal Kumar,Ajay Duseja,Mohamed El-Kassas,Hirokazu Takahasi,Debbie L Shawcross,Jonathan G Stine,Marcela Villota-Rivas,Juan Emilio Miralles-Sanchez,Silvana Pannain,Paul N BrennanMASLD/MASH Collaborators
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p232
REVIEW（综述）
21
Definitions, diagnosis, management, and outcomes of upper gastrointestinal Crohn's disease: an international, expert RAND/UCLA appropriateness study
上消化道克罗恩病的定义、诊断、治疗和转归：一项国际专家兰德/加州大学洛杉矶分校适用性研究
Nathaniel A Cohen,Dominik Bettenworth,Neta Sror,Raneem Khedraki,Qijun Yang,Maria T Abreu,Raja Atreya,Badr Al-Bawardy,Susan J Connor,Geert D'Haens,Iris Dotan,Axel Dignass,Sara El Ouali,Brian Feagan,Roger Feakins,Richard Gearry,Ilyssa O Gordon,Charlotte R H Hedin,Cristian Hernandez-Rocha,Taku Kobayashi,Haim Leibovitzh,Cathy Lu,Nitsan Maharshak,Maliha Naseer,Jacob Ollech,David T Rubin,Shaji Sebastian,Britta Siegmund,Mark S Silverberg,Flavio Steinwurz,Joana Torres,Gill Watermeyer,Tina Aswani Omprakash,Lior Frenkel,Paige Gurizzian,Alexa Silfen,Roie Tzadok,Katherine Falloon,Florian Riederon behalf of the Study of Upper Gastrointestinal Manifestations and Management of Crohn's Disease (SUMM-CD) Group
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p243
22
Mechanisms and pathophysiology leading to development of small intestinal microbial dysbiosis
导致小肠微生物群失调的机制和病理生理学
John A Damianos,Xiao Jing Wang,Michael Camilleri
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p256
THE LANCET Gastroenterology & Hepatology. Volume 11Number4
柳叶刀胃肠病学与肝病学 11卷 4期
https://www.thelancet.com/journals/langas/issue/current
Editorial（社论）
1
Preventive cholera vaccination resumes
预防性霍乱疫苗接种重新启动
The Lancet Gastroenterology & Hepatology
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p267
2
Putting steatotic liver disease on the global NCD agenda
将脂肪变性肝病纳入全球非传染性疾病议程
The Lancet Gastroenterology & Hepatology
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p267
Comment（述评）
3
Menopause and inflammatory bowel disease: more questions than answers
绝经与炎症性肠病：疑问多于答案
Samantha Conley,Kendra J Kamp,Sunanda V Kane
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p268
4
Voices from the frontline: how global funding cuts are reshaping the viral hepatitis response
前线之声：全球资金削减如何重塑病毒性肝炎应对策略
Marion Delphin,Monica Fambrough,Jana Manning,Lindsey Hiebert-Suwondo,Jessica Hicks,Philippa C Matthews
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p269
5
Delivering therapeutic diets for gastrointestinal disease to people with intellectual disabilities
为患有胃肠道疾病的智力障碍人群提供治疗性饮食
Lynette Harper,Ian H Walshe,Leigh Donnelly
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p271
6
Making room under the umbrella for microscopic colitis
在伞状范畴下为显微镜下结肠炎留出一席之地
Jillian Horton,Edward V Loftus Jr
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p274
Correspondence（读者来信）
7
The evolving clinical trial landscape in the MENA region
中东和北非地区临床试验格局的演变
Mohammed Nabil Quraishi,Badr Al-Bawardy
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p277
8
The evolving clinical trial landscape in the MENA region
中东和北非地区临床试验格局的演变
Yasser Fouad,Abdulla Al Hassani,Nawal Alkhalidi,Faisal Abaalkhail,Mohammed Eslam
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p278
9
Difficulties in identifying a signal of activity in the adjuvant setting for biliary tract cancer
在胆道癌辅助治疗中识别活性信号的困难
Julien Edeline,John Bridgewater
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p278
10
Difficulties in identifying a signal of activity in the adjuvant setting for biliary tract cancer – Authors' reply
在胆道癌辅助治疗中识别活性信号的困难——作者回复
Lixing Li,Fei Liang,Zheng Wang,Jia Fan,Jian Zhouon behalf of the ACC investigators
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p279
11
Developing policy for steatotic liver disease: an even better buy?
制定脂肪变性肝病政策：更划算的选择？
Oliver D Tavabie,Megan E Rawcliffe,Mads Israelsen
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p280
Corrections（更正）
12
Correction to Lancet Gastroenterol Hepatol 2025; 10: 634–47
《柳叶刀-胃肠病学与肝病学》2025年；第10卷：第634 - 47页勘误
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：e6
13
Correction to Lancet Gastroenterol Hepatol 2026; 11: 22–33
《柳叶刀-胃肠病学与肝病学》2026年；第11卷：第22 - 33页勘误
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：e6
News（新闻）
14
ECCO 2026
2026年欧洲克罗恩病和结肠炎组织会议
Rob Brierley
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p281
15
Research in Brief
研究简讯
Holly Baker
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p282
In Focus（焦点）
16
Food Matters
食品问题
Low-carbohydrate diets—how low can we go?
低碳水化合物饮食——我们能低到什么程度？
Sanna Nybacka,Heidi M Staudacher
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p283
Articles（论著）
17
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial
皮下古塞库单抗诱导治疗中重度活动性溃疡性结肠炎受试者的有效性和安全性（ASTRO研究）：一项双盲、全程治疗、随机、安慰剂对照的3期试验
Millie Long,Jessica R Allegretti,Silvio Danese,Matthew Germinaro,Thomas Baker,Yelina Alvarez,Mary Kavalam,Chenglong Han,Silke Jörgens,Lingjing Jiang,Hongyan Zhang,Tadakazu Hisamatsu,David T Rubin,Laurent Peyrin-Birouleton behalf of the ASTRO Study Group
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p284
18
Safety, pharmacokinetics, and preliminary efficacy of VS-01, an intraperitoneal liposomal infusion, in patients with decompensated liver cirrhosis, ascites, and covert hepatic encephalopathy: a phase 1b, first-in-human, open-label, non-randomised, single ascending and multiple dose study
VS - 01（一种腹腔内脂质体输注液）在失代偿期肝硬化、腹水和隐性肝性脑病患者中的安全性、药代动力学和初步疗效：一项1b期、首次人体、开放标签、非随机、单次递增和多次给药研究
Frank Erhard Uschner,Martin McCoy,Olaf Tyc,Wenyi Gu,Philip Ferstl,Maximilian Joseph Brol,Johannes Masseli,Kai-Henrik Peiffer,Fabian Finkelmeier,Stefan Zeuzem,Sophie Biguenet,Katharina Staufer,Meriam Kabbaj,Jonel Trebicka
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p299
19
Ileocaecal resection versus infliximab for ileal Crohn's disease: retrospective 10-year follow-up of the LIR!C trial
回盲部切除术与英夫利昔单抗治疗回肠克罗恩病：LIR!C试验的10年回顾性随访
Lotte Oldenburg,Anouck E G Haanappel,Mahsoem Ali,Carolijn Bosman,Christianne J Buskens,Cyriel Y Ponsioen,Geert R D'Haens,Willem A Bemelmanon behalf of the LIR!C study group
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p314
20
Long-term oncological outcomes following algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection: a post-hoc analysis of a nationwide, stepped-wedge cluster-randomised trial
基于算法的护理与常规护理对胰腺切除术后并发症早期识别和治疗的长期肿瘤学预后：一项全国性、阶梯楔形整群随机试验的事后分析
Thijs J Schouten,Kyra J Prinsze,Anne Claire Henry,Lois A Daamen,Marc G Besselink,Bert A Bonsing,Koop Bosscha,Olivier R Busch,Geert A Cirkel,Ronald M van Dam,Casper H van Eijck,Sebastiaan Festen,Bas Groot Koerkamp,Erwin van der Harst,Ignace H J T de Hingh,Geert Kazemier,Mike S L Liem,Vincent E de Meijer,J Sven D Mieog,Gijs A Patijn,Daphne Roos,Jennifer M J Schreinemakers,Martijn W J Stommel,Fennie Wit,C Henri van Werkhoven,I Quintus Molenaar,F Jasmijn Smits,Hjalmar C van Santvoortfor the Dutch Pancreatic Cancer Group
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p323
Review（综述）
21
Chronic liver disease and hepatology care in transgender and gender diverse populations
跨性别者和性别多元人群的慢性肝病和肝病学护理
Thanh N Nguyen,Whitney E Jackson,Nitzan C Roth,Felice Cinque,Monika Sarkar,Niharika Samala,Rita S Lee,Alexandra T Strauss,Jessica Wisocky,Keyur Patel,Giada Sebastiani,Carl G Streed Jr,Jordan E Lake,Tzu-Hao Lee
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p334
THE LANCET Gastroenterology & Hepatology. Volume 11Number5
柳叶刀·胃肠病学与肝病学 11卷 5期
https://www.thelancet.com/journals/langas/issue/current
EDITORIAL(社论)
1
Early-onset colorectal cancer: rising rates require rising awareness
早发性结直肠癌：发病率上升需提高认知
The Lancet Gastroenterology & Hepatology
The Lancet Gastroenterology & Hepatology. May 2026, Vol 11(5)：p345
COMMENT（述评）
2
Transanal total mesorectal excision in the era of robotic surgery
机器人手术时代的经肛全直肠系膜切除术
Patricia Sylla
The Lancet Gastroenterology & Hepatology. May 2026, Vol 11(5)：p346
3
Indocyanine green works: redefining research priorities in colorectal surgery
吲哚菁绿起效：重新定义结直肠外科研究重点
Zoe Garoufalia
The Lancet Gastroenterology & Hepatology. May 2026, Vol 11(5)：p347
4
Africa must not be left out of the hepatitis B cure era
非洲不能被排除在乙肝治愈时代之外
Mohamed El-Kassas,Hend Shousha,Asgeir Johannessenon behalf of the Hepatitis B in Africa Collaborative Network (HEPSANET)
The Lancet Gastroenterology & Hepatology. May 2026, Vol 11(5)：p349
5
Global gains, metabolic pains: unmasking the hidden burden on liver health
全球获益，代谢之痛：揭开肝脏健康隐性负担的面纱
Maja Thiele,Ajeet Singh Bhadoria,Jessica Mellinger,Shira Zelber-Sagi,Pinelopi Manousou,Debbie L Shawcross,Neeraj Bhala
The Lancet Gastroenterology & Hepatology. May 2026, Vol 11(5)：p351
CORRECTIONS（更正）
6
Correction to Lancet Gastroenterol Hepatol 2022; 7: 202–03
对《柳叶刀·胃肠病学和肝病学》2022年；第7卷：202 - 03的勘误
The Lancet Gastroenterology & Hepatology. May 2026, Vol 11(5)：e7
7
Correction to Lancet Gastroenterol Hepatol 2024; 9: 1041–51
对《柳叶刀·胃肠病学和肝病学》2024年；第9卷：1041 - 51的勘误
The Lancet Gastroenterology & Hepatology. May 2026, Vol 11(5)：e7
IN FOCUS（焦点）
Film（电影）
8
André is an Idiot
《安德烈是个白痴》
Joe Moody
The Lancet Gastroenterology & Hepatology. May 2026, Vol 11(5)：p354
ARTICLES（论著）
9
Transanal total mesorectal excision versus laparoscopic total mesorectal excision for mid and low rectal cancer (COLOR III): short-term outcomes of an international, multicentre, phase 3, randomised, controlled, non-inferiority trial
经肛全直肠系膜切除术与腹腔镜全直肠系膜切除术治疗中低位直肠癌（COLOR III）：一项国际多中心3期随机对照非劣效性试验的短期结果
Jurriaan B Tuynman,Hongwei Yao,Laura R Moolenaar,Colin Sietses,Roel Hompes,Felix Aigner,Antonio Caycedo–Marulanda,Chien-Chih Chen,Muneer Deeb,Pascal G Doornebosch,Bo Feng,Chi-Chung Foo,Alois Fürst,Masaaki Ito,Francisco B de Lacy,Pedro Leão,Justin A Maykel,Andrea Muratore,Stefan E van Oostendorp,Sung Chan Park,MichałPędziwiatr,MingYang Ren,Gerald Seitinger,Hein B A C Stockmann,Aaldert K Talsma,Andreas Türler,Weidong Tong,Quan Wang,Qing Xu,Hongyu Zhang,Jan-Hein T M van Waesberghe,Mahsoem Ali,Jos W R Twisk,Zhongtao Zhang,Antonio M de Lacy,George B Hanna,Hendrik J Bonjeron behalf of the COLOR III Study Group
The Lancet Gastroenterology & Hepatology. May 2026, Vol 11(5)：p355
10
Indocyanine green fluorescence angiography for anastomotic perfusion assessment in colorectal surgery: a systematic review with meta-analysis, meta-regression, and trial sequential analyses
吲哚菁绿荧光血管造影用于结直肠手术吻合口灌注评估：一项包含荟萃分析、荟萃回归分析和试验序贯分析的系统综述
Éanna J Ryan,Odhrán K Ryan,Neil Corrigan,Gemma Ainsworth,Denise E Hilling,Alexander L Vahrmeijer,Jyrki Kössi,Jun Watanabe,David Jayne,Ronan A Cahill
The Lancet Gastroenterology & Hepatology. May 2026, Vol 11(5)：p367
11
Natural history of chronic hepatitis B in untreated adults without cirrhosis according to baseline hepatitis B virus DNA and alanine aminotransferase concentrations: a systematic review and meta-analysis
根据基线乙肝病毒DNA和丙氨酸氨基转移酶浓度，未接受治疗的无肝硬化成年慢性乙肝患者的自然病程：一项系统综述和荟萃分析
Daniela Yucuma,Arthur Rakover,Zakary Ismail Warsop,Yu Ri Im,Si Emma Chen,Rukmini Jagdish,Gibril Ndow,Maud Lemoine,Hailemichael Desalegn,Asgeir Johannessen,Hwai-I Yang,Yasuhito Tanaka,Roger Chou,Philippa Easterbrook,Yusuke Shimakawa
The Lancet Gastroenterology & Hepatology. May 2026, Vol 11(5)：p380
12
Efficacy of antiviral therapy in adults with chronic hepatitis B according to baseline hepatitis B virus DNA and alanine aminotransferase concentrations: a systematic review and meta-analysis
根据基线乙肝病毒DNA和丙氨酸氨基转移酶浓度，慢性乙肝成年患者抗病毒治疗的疗效：一项系统综述和荟萃分析
Yu Ri Im,Si Emma Chen,Rukmini Jagdish,Daniela Yucuma,Arthur Rakover,Zakary Ismail Warsop,Roger Chou,Philippa Easterbrook,Yusuke Shimakawa
The Lancet Gastroenterology & Hepatology. May 2026, Vol 11(5)：p397
REVIEW（综述）
13
Who to test and reflex testing for hepatitis D virus infection: evidence and rationale to inform policy recommendations and future directions
丁型肝炎病毒感染的检测对象及复检策略：为政策建议和未来方向提供依据与理论支撑
Sahar Bajis,Niklas Luhmann,Emi Okamoto,Robia Islam,Olufunmilayo Lesi,Philippa Easterbrook
The Lancet Gastroenterology & Hepatology. May 2026, Vol 11(5)：p417
14
How to test for hepatitis D virus infection: evidence and rationale to inform policy recommendations and future directions
如何检测丁型肝炎病毒感染：为制定政策建议和未来方向提供证据和依据
Emi E Okamoto,Robia Islam,Sahar Bajis,Niklas Luhmann,Ashley Kallarakal,Frédéric Le Gal,Philippa Easterbrook
The Lancet Gastroenterology & Hepatology. May 2026, Vol 11(5)：p426
2026-03-17
THE LANCET Gastroenterology & Hepatology. Volume 11Number1
柳叶刀胃肠病学与肝病学 11卷 1期
https://www.thelancet.com/journals/langas/issue/current
EDITORIAL(社论)
1
Accelerating MASH trials: from biopsy to biomarkers
加速MASH（代谢障碍相关脂肪性肝炎）试验：从活检到生物标志物
The Lancet Gastroenterology & Hepatology
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p1
COMMENT（述评）
2
Optimising treatment in Crohn's disease: is the main issue early versus late or biologic naive versus biologic experienced?
优化克罗恩病的治疗：主要问题在于早期治疗与晚期治疗，还是生物制剂初治患者与生物制剂经治患者？
Marte Lie Høivik
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p2
3
Ileal bile acid transporter inhibitors for cholestatic pruritus in primary biliary cholangitis
针对原发性胆汁性胆管炎中胆汁淤积性瘙痒的回肠胆汁酸转运蛋白抑制剂
Ansgar W Lohse,David N Assis
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p3
4
Dual targeting of TNF and IL-23 by a bispecific antibody in ulcerative colitis
双特异性抗体在溃疡性结肠炎中同时靶向TNF和IL-23
Raja Atreya,Markus F Neurath
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p5
5
The essential medicines list for inflammatory bowel disease: time to raise the standards of global care
炎症性肠病基本药物清单：是时候提高全球护理标准了
Nanne K de Boer,Richard B Gearry,Charles N Bernstein,Rupa Banerjee,David T Rubin,Gilaad G Kaplanon behalf of the Globalization Cluster of the International Organization of IBD
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p7
NEWS（新闻）
6
The Liver Meeting 2025
2025年肝脏会议
Rob Brierley
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p10
IN FOCUS（焦点）
7
Food Matters
食物很重要
Dietary management of constipation: time for clinical guidelines to catch up with evidence
便秘的饮食治疗：是时候让临床指南跟上证据的步伐了
Eirini Dimidi,Kevin Whelan
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p11
ARTICLES（论著）
8
Vedolizumab in early and late Crohn's disease (LOVE-CD): a phase 4 open-label cohort study
维多珠单抗在早期和晚期克罗恩病中的应用（LOVE-CD）：一项4期开放性队列研究
Geert R D'Haens,Mark Löwenberg,Filip Baert,Peter Bossuyt,Tamás Molnár,Frank Hoentjen,Esmé Clasquin,Krisztina B Gecse,Melanie S Hulshoff,Gert De Hertogh,Matthias Lenfant,Lotte Oldenburg,Séverine Vermeire
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p12
9
Linerixibat in patients with primary biliary cholangitis and cholestatic pruritus (GLISTEN): 利尼西巴特治疗原发性胆汁性胆管炎和胆汁淤积性瘙痒患者（GLISTEN）：一项随机、多中心、双盲、安慰剂对照的3期试验
a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial
Gideon M Hirschfield,Christopher L Bowlus,David E J Jones,Andreas E Kremer,Marlyn J Mayo,Atsushi Tanaka,Pietro Andreone,Jidong Jia,Qinglong Jin,Ricardo U Macías-Rodríguez,Alexander R Cobitz,Brooke M Currie,Ciara Gorey,Ivana Lazic,Danielle Podmore,Andrea Ribeiro,Jennifer B Shannon,Brandon Swift,Megan M McLaughlin,Cynthia Levyfor the GLISTEN Study Group
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p22
10
Safety and pharmacokinetics of SOR102, an oral bispecific inhibitor of TNF and interleukin-23 in healthy participants and patients with ulcerative colitis: a first-in-human, double-blind, randomised, placebo-controlled, phase 1 trial
SOR102（一种口服双特异性肿瘤坏死因子和白细胞介素-23抑制剂）在健康受试者和溃疡性结肠炎患者中的安全性和药代动力学：一项首次人体、双盲、随机、安慰剂对照的1期试验
Vipul Jairath,Silvio Danese,Geert R D’Haens,Brian G Feagan,Laurent Peyrin-Biroulet,Bruce E Sands,Ingrid Gaemers,Matt Westfall,Allyson Q Terry,Kevin J Roberts,Sara Barbat,Pamela Wedel,Jacqueline M Benson,Carlos Sattler
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p34
11
Cilofexor in non-cirrhotic primary sclerosing cholangitis (PRIMIS): a randomised, double-blind, multicentre, placebo-controlled, phase 3 trial
西洛芬酸在非肝硬化原发性硬化性胆管炎中的应用（PRIMIS）：一项随机、双盲、多中心、安慰剂对照的3期试验
Michael Trauner,Cynthia Levy,Atsushi Tanaka,Zachary Goodman,Douglas Thorburn,Deepak Joshi,Kimmo Salminen,Kidist Yimam,Hiroyuki Isayama,Aldo J Montano-Loza,Stephen Caldwell,Mark Danta,Martti Farkkila,Juan F Gallegos-Orozco,Stuart C Gordon,Holger Hinrichsen,Pietro Invernizzi,Raj Vuppalanchi,Kaiyi Zhu,Jun Xu,Xiangyu Liu,Xiaomin Lu,Gerald Crans,Shahla Bolbolan,Lisa Boyette,Muhsen Alani,William T Barchuk,Timothy R Watkins,Mark C Genovese,Christopher L Bowlus
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p46
REVIEW（综述）
12
Age-related changes of the gastrointestinal tract
胃肠道的年龄相关变化
Alberto Pilotto,Carlo Custodero,Lucilla Crudele,Wanda Morganti,Nicola Veronese,Marilisa Franceschi
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p59
13
Fatigue in people with primary biliary cholangitis: a position paper from the European Reference Network for Rare Liver Diseases
原发性胆汁性胆管炎患者的疲劳问题：欧洲罕见肝病参考网络立场文件
Ozgur M Koc,Anne-Kristin Toussaint,Aurelie Untas,Piotr Milkiewicz,Henriette Ytting,Laura Buck,David E Jones,Gideon Hirschfield,Angela Leburgue,Christoph Schramm,Frederik Nevens,Adriaan J van der Meer,Alessio Gerussi,Jef Verbeek
The Lancet Gastroenterology & Hepatology. Nov 2025, Vol 11(1):p71
THE LANCET Gastroenterology & Hepatology. Volume 11Number2
柳叶刀胃肠病学与肝病学 11卷 2期
https://www.thelancet.com/journals/langas/issue/current
EDITORIAL(社论)
1
ACIP's HBV birth-dose vaccine recommendations: a fiasco
美国免疫接种咨询委员会（ACIP）的乙肝疫苗出生剂量推荐：一场闹剧
The Lancet Gastroenterology & Hepatology
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p87
COMMENT（述评）
2
Expanding the therapeutic arsenal for paediatric ulcerative colitis
扩充儿童溃疡性结肠炎的治疗武器库
Stephanie A Vuijk,Esmée H Boute,Lissy de Ridder
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p88
3
Closing the Middle East and north Africa representation gap in clinical trials in inflammatory bowel disease
缩小炎症性肠病临床试验中中东和北非地区代表不足的差距
Mohammad Shebab,Ahmed Al-Hindawi,Shane W Goodwin,Yuhong Yuan,Talat Bessissow,Laurent Peyrin-Biroulet,Vipul Jairath
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p89
4
Colorectal cancer screening in LGBTQIA+ people: an urgent call for equity
对LGBTQIA+人群进行结直肠癌筛查：迫切呼吁公平
Vidhi Singh,Jayraan Badiee,Alexander Goldowsky,David Russo,Folasade P May
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p91
CORRESPONDENCE（读者来信）
5
Efficacy differentiation of sterile faecal filtrates in Clostridioides difficile infection
无菌粪便滤液在艰难梭菌感染中的疗效差异
Stefan Schreiber,Philip Rosenstiel,Stephan J Ott,Georg H Waetzig
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p94
6
Efficacy differentiation of sterile faecal filtrates in Clostridioides difficile infection – Authors’ reply
无菌粪便滤液在艰难梭菌感染中的疗效差异——作者回复
Dina Kao,Huiping Xu,Thomas Louie
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p94
7
Endoscopic palliation of malignant gastric outlet obstruction: harmonising outcomes
恶性胃出口梗阻的内镜下姑息治疗：统一疗效标准
Zachary L Smith
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p95
8
Clinical remission in ulcerative colitis: restoring precision in trial terminology
溃疡性结肠炎的临床缓解：恢复试验术语的精确性
Sailish Honap,Vipul Jairath,Fernando Magro,Silvio Danese,Laurent Peyrin-Biroulet
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p96
CORRECTIONS（更正）
9
Correction to Lancet Gastroenterol Hepatol 2019; 4: 364–75
对《柳叶刀-胃肠病学与肝病学》2019年；4卷：364-75页的更正
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：e1
10
Correction to Lancet Gastroenterol Hepatol 2025; 10: 431–41
对《柳叶刀-胃肠病学与肝病学》2025年；10卷：431-41页的更正
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：e1
NEWS（新闻）
11
Research in Brief
研究简讯
Holly Baker
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p98
IN FOCUS（焦点）
12
Patient Perspectives
患者视角
The label of a diagnosis
诊断标签
Cheryl Reeves
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p99
ARTICLES（论著）
13
Efficacy and safety of mirikizumab in paediatric participants with moderately-to-severely active ulcerative colitis (SHINE-1): a multicentre, open-label, non-randomised phase 2 trial
Mirikizumab治疗中重度活动性溃疡性结肠炎儿童患者的疗效和安全性（SHINE-1）：一项多中心、开放标签、非随机2期试验
Jess L Kaplan,Athos Bousvaros,Dan Turner,Marla Dubinsky,Amy Larkin,Jordan Johns,Yuki Otani,Wallace Crandall,Wendy J Komocsar,Jeffrey S Hyams
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p100
14
Glecirasib with or without cetuximab in previously treated locally advanced or metastatic colorectal cancer with KRASG12C mutation (JAB-21822-1002 and JAB-21822-1007): two open-label, non-randomised phase 1/2 trials
Glecirasib联合或不联合西妥昔单抗治疗既往接受过治疗的KRASG12C突变局部晚期或转移性结直肠癌（JAB-21822-1002和JAB-21822-1007）：两项开放标签、非随机1/2期试验
Jian Li,Zhenghang Wang,Jing Huang,Yi Ba,Baoshan Cao,Suxia Luo,Wenhua Li,Chunmei Bai,Zhengbo Song,Jianping Xiong,Liangjun Zhu,Guangyu An,Yanqiao Zhang,Zhihua Li,Yongsheng Li,Yanhong Gu,Changlu Hu,Xingya Li,Chenghui Huang,Qihan Fu,Xianli Yin,Xinjun Liang,Diansheng Zhong,Huaqiu Shi,Xiaoyan Li,Zhen Li,Lian Liu,Feng Wang,Rong Liang,Guohao Xia,Zhen Wang,Andrea Wang-Gillam,Yuli Ding,Zhiyue Rao,Wenhui Pan,Shuang Lu,Xin Sun,Lin Shen
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p110
15
Adjuvant camrelizumab combined with capecitabine in patients with intrahepatic cholangiocarcinoma after surgical resection in China (ACC): a single-arm, single-centre, open-label, phase 2 trial
卡瑞利珠单抗联合卡培他滨辅助治疗中国肝内胆管癌术后患者（ACC）：一项单臂、单中心、开放标签、2期试验
Zheng Wang,Lixing Li,Peiran Huang,Honghu Tu,Xiangyu Zhang,Lei Yu,Fei Liang,Cheng Huang,Shuangjian Qiu,Qinghai Ye,Zhenbin Ding,Xiaowu Huang,Yinghong Shi,Kang Song,Huichuan Sun,Xiaoying Wang,Yongfeng Xu,Yao Yu,Qiang Gao,Lan Zhang,Jia Fan,Jian Zhou
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p124
16
Tinengotinib for adults with advanced or metastatic cholangiocarcinoma: a multicentre, open-label, phase 2 trial
Tinengotinib治疗晚期或转移性胆管癌成人患者：一项多中心、开放标签、2期试验
Milind Javle,Christos Fountzilas,Chih-Yi Liao,Meredith Pelster,Daneng Li,Dustin Deming,Vaibhav Sahai,Lionel Kankeu Fonkoua,Allen Cohn,Parvez Mantry,Donald Richards,Edwin Kingsley,Frank Wu,Peng Peng,Katie Hennessy,Hui Wang,Caixia Sun,Shumao Ni,Jean Fan,Amit Mahipal
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p137
REVIEW（综述）
17
Current and emerging therapeutic landscape for metabolic dysfunction-associated steatohepatitis
代谢功能障碍相关脂肪性肝炎当前及新兴治疗格局
Wenhao Li,William Alazawi,Rohit Loomba
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p150
VIEWPOINT（观点）
18
Ulcerative colitis: moving beyond the mucosal dogma
溃疡性结肠炎：超越黏膜教条
Elisabeth Eggermont,Krisztina Gecse,Noa Krugliak Cleveland,Frauke Petersen,João Sabino,AndréD'Hoore,Torsten Kucharzik,Mariangela Allocca,Gabriele Bislenghi,Kerri Novak,Gert De Hertogh,Christian Maaser,Bram Verstockt
The Lancet Gastroenterology & Hepatology. Feb 2026, Vol 11(2)：p163
THE LANCET Gastroenterology & Hepatology. Volume 11Number3
柳叶刀胃肠病学与肝病学 11卷 3期
https://www.thelancet.com/journals/langas/issue/current
EDITORIAL(社论)
1
Alcohol guidance in US dietary guidelines: a step backwards
美国膳食指南中的酒精建议：倒退的一步
The Lancet Gastroenterology & Hepatology
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p175
2
Thanks to our peer reviewers and contributors
感谢我们的同行评审专家和投稿者
The Lancet Gastroenterology & Hepatology
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p175
COMMENT（述评）
3
Appendicectomy: a disease-modifying treatment for ulcerative colitis?
阑尾切除术：溃疡性结肠炎的一种疾病修饰疗法？
Alexandra Damasio Todescatto,Paulo Gustavo Kotze
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p176
4
Cyclic exclusive enteral nutrition: a novel approach to maintaining remission in paediatric Crohn's disease
循环全肠内营养：维持儿童克罗恩病缓解的新方法
Anissa M Armet,Eytan Wine
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p177
5
Viral hepatitis in Roma communities: vulnerabilities and improving care access
罗姆人社区中的病毒性肝炎：易感性及改善医疗可及性
Pavol Kristian,Ivana Hockickova,Monika Halanova,Sylvia Drazilova,Ondrej Zahornacky,Peter Jarcuska
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p179
6
Thank you to The Lancet Gastroenterology & Hepatology's statistical and peer reviewers in 2025
感谢《柳叶刀 - 胃肠病学和肝病学》2025 年的统计学和同行评审专家
The Lancet Gastroenterology & Hepatology's Editors
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：e2
CORRESPONDENCE（读者来信）
7
Antipruritic effects of the ileal bile acid transporter inhibitor linerixibat
回肠胆汁酸转运体抑制剂利那西巴特的抗瘙痒作用
Gideon M Hirschfield,Andreas E Kremer,Cynthia Levy
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p182
8
Vedolizumab treatment outcomes in early versus late Crohn's disease
维多珠单抗治疗早期与晚期克罗恩病的疗效
Nurulamin M Noor,Ailsa L Hart,James C Lee,Miles Parkes
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p182
9
Vedolizumab treatment outcomes in early versus late Crohn's disease
维多珠单抗治疗早期与晚期克罗恩病的疗效
Rirong Chen,Kenneth Croitoru,Sun-Ho Lee
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p183
10
Vedolizumab treatment outcomes in early versus late Crohn's disease – Authors' reply
维多珠单抗治疗早期与晚期克罗恩病的疗效——作者回复
Geert R D'Haens,Lotte Oldenburg,Melanie S Hulshoffon behalf of the LOVE-CD collaborators
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p184
11
Global perspectives on sustainable IBD care
全球视角下的可持续炎症性肠病（IBD）诊疗
Olga M Nardone,Silvio Danese,Beatriz Gros,Tommaso L Parigion behalf of the Sustainable IBD Study Group
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p185
12
The impact of 2025 US NIDDK funding cuts
2025 年美国国家糖尿病、消化及肾脏疾病研究所（NIDDK）经费削减的影响
Rogelio Perez,Christopher W Chan,Aakash Reddy,David T Zhu
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p186
CORRECTIONS（更正）
13
Correction to Lancet Gastroenterol Hepatol 2026; 11: 34–45
对《柳叶刀 - 胃肠病学和肝病学》2026 年；11卷：34 - 45 页的更正
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：e5
14
Correction to Lancet Gastroenterol Hepatol 2026; 11: 89–91
对《柳叶刀 - 胃肠病学和肝病学》2026 年；11卷：89 - 91 页的更正
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：e5
NEWS（新闻）
15
ASCO Gastrointestinal Cancers Symposium 2026
2026 年美国临床肿瘤学会（ASCO）胃肠道肿瘤研讨会
Rob Brierley
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p188
IN FOCUS（焦点）
Book（书籍）
16
Stoma: life saver, not a barrier
造口：救命手段，而非障碍
Lucy Mae Spurgeon
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p189
ARTICLES（论著）
17
Appendicectomy versus switching to a JAK inhibitor in inducing remission in patients with active ulcerative colitis after biologic therapy failure (COSTA): 1-year results of a multicentre, prospective, cohort study
生物制剂治疗失败后，阑尾切除术与换用 JAK 抑制剂诱导活动期溃疡性结肠炎患者缓解的对比（COSTA）：一项多中心、前瞻性、队列研究的 1 年结果
Eva Visser,Maud A Reijntjes,Lianne Heuthorst,Merle E Stellingwerf,Rachel West,Koen van Dongen,Rogier M P H Crolla,Susan van Dieren,Jarmila D W van der Bilt,Willem A Bemelman,Geert R D'Haens,Christianne J Buskensfor the COSTA Study Group
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p190
18
Cyclic exclusive enteral nutrition versus partial enteral nutrition to maintain long-term drug-free remission in paediatric Crohn's disease (CD-HOPE): an open-label, endpoint-blinded, randomised controlled trial
循环全肠内营养与部分肠内营养维持儿童克罗恩病长期无药物缓解的对比（CD - HOPE）：一项开放标签、终点盲法、随机对照试验
Bénédicte Pigneur,Christine Martinez-Vinson,Aurélie Bourmaud,Alain Dabadie,Rémi Duclaux-Loras,Jean-Pierre Hugot,Céline Roman,Clémentine Dumant,Claire Spyckerelle,Vincent Guinard-Samuel,Stéphanie Willot,Claire Dupont,Anne Breton,Nicolas Caron,Emilie Chaillou,Laurent Rebouissoux,Valérie Bertrand,Valérie Triolo,Justine Pages,Djamal Djeddi,Marjorie Bonneton,Stéphanie Uhlen,Natacha Catteau,Stéphanie Coopman,Patricia Lepage,Jérôme Viala,Frank M Ruemmele
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p204
19
ALG-000184 (pevifoscorvir sodium) monotherapy in participants with chronic HBV infection: a phase 1, multicentre, randomised, dose escalation trial
ALG - 000184（佩维福司科韦钠）单药治疗慢性乙型肝炎病毒感染者：一项 1 期、多中心、随机、剂量递增试验
Man-Fung Yuen,Kosh Agarwal,Alina Jucov,Jinlin Hou,Junqi Niu,Yanhua Ding,Alexei Haceatrean,Xie'er Liang,Jia Xu,Min Wu,Kha Le,Tse-I Lin,Lawrence Blatt,Sushmita Chanda,John Fry,Ed Gane
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p218
20
Best buys for metabolic dysfunction-associated steatotic liver disease and metabolic dysfunction-associated steatohepatitis: a global Delphi study
代谢功能障碍相关脂肪性肝病和代谢功能障碍相关脂肪性肝炎的最佳干预措施：一项全球德尔菲研究
Jeffrey V Lazarus,Leire Agirre-Garrido,Trenton M White,Anish K Arora,Melina I Manolas,Luis Antonio Diaz,Juan Pablo Arab,Shira Zelber-Sagi,Naim Alkhouri,C Wendy Spearman,Jörn M Schattenberg,Loreta A Kondili,Patrizia Carrieri,Holly F Lofton,Priya Jaisinghani,Sonal Kumar,Ajay Duseja,Mohamed El-Kassas,Hirokazu Takahasi,Debbie L Shawcross,Jonathan G Stine,Marcela Villota-Rivas,Juan Emilio Miralles-Sanchez,Silvana Pannain,Paul N BrennanMASLD/MASH Collaborators
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p232
REVIEW（综述）
21
Definitions, diagnosis, management, and outcomes of upper gastrointestinal Crohn's disease: an international, expert RAND/UCLA appropriateness study
上消化道克罗恩病的定义、诊断、治疗和转归：一项国际专家兰德/加州大学洛杉矶分校适用性研究
Nathaniel A Cohen,Dominik Bettenworth,Neta Sror,Raneem Khedraki,Qijun Yang,Maria T Abreu,Raja Atreya,Badr Al-Bawardy,Susan J Connor,Geert D'Haens,Iris Dotan,Axel Dignass,Sara El Ouali,Brian Feagan,Roger Feakins,Richard Gearry,Ilyssa O Gordon,Charlotte R H Hedin,Cristian Hernandez-Rocha,Taku Kobayashi,Haim Leibovitzh,Cathy Lu,Nitsan Maharshak,Maliha Naseer,Jacob Ollech,David T Rubin,Shaji Sebastian,Britta Siegmund,Mark S Silverberg,Flavio Steinwurz,Joana Torres,Gill Watermeyer,Tina Aswani Omprakash,Lior Frenkel,Paige Gurizzian,Alexa Silfen,Roie Tzadok,Katherine Falloon,Florian Riederon behalf of the Study of Upper Gastrointestinal Manifestations and Management of Crohn's Disease (SUMM-CD) Group
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p243
22
Mechanisms and pathophysiology leading to development of small intestinal microbial dysbiosis
导致小肠微生物群失调的机制和病理生理学
John A Damianos,Xiao Jing Wang,Michael Camilleri
The Lancet Gastroenterology & Hepatology. Mar 2026, Vol 11(3)：p256
THE LANCET Gastroenterology & Hepatology. Volume 11Number4
柳叶刀胃肠病学与肝病学 11卷 4期
https://www.thelancet.com/journals/langas/issue/current
Editorial（社论）
1
Preventive cholera vaccination resumes
预防性霍乱疫苗接种重新启动
The Lancet Gastroenterology & Hepatology
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p267
2
Putting steatotic liver disease on the global NCD agenda
将脂肪变性肝病纳入全球非传染性疾病议程
The Lancet Gastroenterology & Hepatology
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p267
Comment（述评）
3
Menopause and inflammatory bowel disease: more questions than answers
绝经与炎症性肠病：疑问多于答案
Samantha Conley,Kendra J Kamp,Sunanda V Kane
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p268
4
Voices from the frontline: how global funding cuts are reshaping the viral hepatitis response
前线之声：全球资金削减如何重塑病毒性肝炎应对策略
Marion Delphin,Monica Fambrough,Jana Manning,Lindsey Hiebert-Suwondo,Jessica Hicks,Philippa C Matthews
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p269
5
Delivering therapeutic diets for gastrointestinal disease to people with intellectual disabilities
为患有胃肠道疾病的智力障碍人群提供治疗性饮食
Lynette Harper,Ian H Walshe,Leigh Donnelly
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p271
6
Making room under the umbrella for microscopic colitis
在伞状范畴下为显微镜下结肠炎留出一席之地
Jillian Horton,Edward V Loftus Jr
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p274
Correspondence（读者来信）
7
The evolving clinical trial landscape in the MENA region
中东和北非地区临床试验格局的演变
Mohammed Nabil Quraishi,Badr Al-Bawardy
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p277
8
The evolving clinical trial landscape in the MENA region
中东和北非地区临床试验格局的演变
Yasser Fouad,Abdulla Al Hassani,Nawal Alkhalidi,Faisal Abaalkhail,Mohammed Eslam
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p278
9
Difficulties in identifying a signal of activity in the adjuvant setting for biliary tract cancer
在胆道癌辅助治疗中识别活性信号的困难
Julien Edeline,John Bridgewater
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p278
10
Difficulties in identifying a signal of activity in the adjuvant setting for biliary tract cancer – Authors' reply
在胆道癌辅助治疗中识别活性信号的困难——作者回复
Lixing Li,Fei Liang,Zheng Wang,Jia Fan,Jian Zhouon behalf of the ACC investigators
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p279
11
Developing policy for steatotic liver disease: an even better buy?
制定脂肪变性肝病政策：更划算的选择？
Oliver D Tavabie,Megan E Rawcliffe,Mads Israelsen
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p280
Corrections（更正）
12
Correction to Lancet Gastroenterol Hepatol 2025; 10: 634–47
《柳叶刀-胃肠病学与肝病学》2025年；第10卷：第634 - 47页勘误
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：e6
13
Correction to Lancet Gastroenterol Hepatol 2026; 11: 22–33
《柳叶刀-胃肠病学与肝病学》2026年；第11卷：第22 - 33页勘误
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：e6
News（新闻）
14
ECCO 2026
2026年欧洲克罗恩病和结肠炎组织会议
Rob Brierley
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p281
15
Research in Brief
研究简讯
Holly Baker
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p282
In Focus（焦点）
16
Food Matters
食品问题
Low-carbohydrate diets—how low can we go?
低碳水化合物饮食——我们能低到什么程度？
Sanna Nybacka,Heidi M Staudacher
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p283
Articles（论著）
17
Efficacy and safety of subcutaneous guselkumab induction therapy in participants with moderately to severely active ulcerative colitis (ASTRO): a double-blind, treat-through, randomised, placebo-controlled, phase 3 trial
皮下古塞库单抗诱导治疗中重度活动性溃疡性结肠炎受试者的有效性和安全性（ASTRO研究）：一项双盲、全程治疗、随机、安慰剂对照的3期试验
Millie Long,Jessica R Allegretti,Silvio Danese,Matthew Germinaro,Thomas Baker,Yelina Alvarez,Mary Kavalam,Chenglong Han,Silke Jörgens,Lingjing Jiang,Hongyan Zhang,Tadakazu Hisamatsu,David T Rubin,Laurent Peyrin-Birouleton behalf of the ASTRO Study Group
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p284
18
Safety, pharmacokinetics, and preliminary efficacy of VS-01, an intraperitoneal liposomal infusion, in patients with decompensated liver cirrhosis, ascites, and covert hepatic encephalopathy: a phase 1b, first-in-human, open-label, non-randomised, single ascending and multiple dose study
VS - 01（一种腹腔内脂质体输注液）在失代偿期肝硬化、腹水和隐性肝性脑病患者中的安全性、药代动力学和初步疗效：一项1b期、首次人体、开放标签、非随机、单次递增和多次给药研究
Frank Erhard Uschner,Martin McCoy,Olaf Tyc,Wenyi Gu,Philip Ferstl,Maximilian Joseph Brol,Johannes Masseli,Kai-Henrik Peiffer,Fabian Finkelmeier,Stefan Zeuzem,Sophie Biguenet,Katharina Staufer,Meriam Kabbaj,Jonel Trebicka
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p299
19
Ileocaecal resection versus infliximab for ileal Crohn's disease: retrospective 10-year follow-up of the LIR!C trial
回盲部切除术与英夫利昔单抗治疗回肠克罗恩病：LIR!C试验的10年回顾性随访
Lotte Oldenburg,Anouck E G Haanappel,Mahsoem Ali,Carolijn Bosman,Christianne J Buskens,Cyriel Y Ponsioen,Geert R D'Haens,Willem A Bemelmanon behalf of the LIR!C study group
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p314
20
Long-term oncological outcomes following algorithm-based care versus usual care for the early recognition and management of complications after pancreatic resection: a post-hoc analysis of a nationwide, stepped-wedge cluster-randomised trial
基于算法的护理与常规护理对胰腺切除术后并发症早期识别和治疗的长期肿瘤学预后：一项全国性、阶梯楔形整群随机试验的事后分析
Thijs J Schouten,Kyra J Prinsze,Anne Claire Henry,Lois A Daamen,Marc G Besselink,Bert A Bonsing,Koop Bosscha,Olivier R Busch,Geert A Cirkel,Ronald M van Dam,Casper H van Eijck,Sebastiaan Festen,Bas Groot Koerkamp,Erwin van der Harst,Ignace H J T de Hingh,Geert Kazemier,Mike S L Liem,Vincent E de Meijer,J Sven D Mieog,Gijs A Patijn,Daphne Roos,Jennifer M J Schreinemakers,Martijn W J Stommel,Fennie Wit,C Henri van Werkhoven,I Quintus Molenaar,F Jasmijn Smits,Hjalmar C van Santvoortfor the Dutch Pancreatic Cancer Group
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p323
Review（综述）
21
Chronic liver disease and hepatology care in transgender and gender diverse populations
跨性别者和性别多元人群的慢性肝病和肝病学护理
Thanh N Nguyen,Whitney E Jackson,Nitzan C Roth,Felice Cinque,Monika Sarkar,Niharika Samala,Rita S Lee,Alexandra T Strauss,Jessica Wisocky,Keyur Patel,Giada Sebastiani,Carl G Streed Jr,Jordan E Lake,Tzu-Hao Lee
The Lancet Gastroenterology & Hepatology. Apr 2026, Vol 11(4)：p334
临床3期临床2期临床结果
100 项与 Cilofexor tromethamine 相关的药物交易
登录后查看更多信息
外链
| KEGG | Wiki | ATC | Drug Bank |
|---|---|---|---|
| - | - | - |
研发状态
10 条进展最快的记录, 后查看更多信息
登录
| 适应症 | 最高研发状态 | 国家/地区 | 公司 | 日期 |
|---|---|---|---|---|
| 原发性硬化性胆管炎 | 临床3期 | 美国 | 2019-03-27 | |
| 原发性硬化性胆管炎 | 临床3期 | 日本 | 2019-03-27 | |
| 原发性硬化性胆管炎 | 临床3期 | 澳大利亚 | 2019-03-27 | |
| 原发性硬化性胆管炎 | 临床3期 | 奥地利 | 2019-03-27 | |
| 原发性硬化性胆管炎 | 临床3期 | 比利时 | 2019-03-27 | |
| 原发性硬化性胆管炎 | 临床3期 | 加拿大 | 2019-03-27 | |
| 原发性硬化性胆管炎 | 临床3期 | 丹麦 | 2019-03-27 | |
| 原发性硬化性胆管炎 | 临床3期 | 芬兰 | 2019-03-27 | |
| 原发性硬化性胆管炎 | 临床3期 | 法国 | 2019-03-27 | |
| 原发性硬化性胆管炎 | 临床3期 | 德国 | 2019-03-27 |
登录后查看更多信息
临床结果
临床结果
适应症
分期
评价
查看全部结果
| 研究 | 分期 | 人群特征 | 评价人数 | 分组 | 结果 | 评价 | 发布日期 |
|---|
临床3期 | 416 | 積艱夢鏇鹽膚齋齋築顧(顧繭願鏇餘淵製衊範蓋) = The most common adverse events were pruritus (cilofexor: 136 [49%] of 277 patients; placebo: 50 [36%] of 139 patients; grade 3 or higher in 11 [4%] patients in the cilofexor group and one [1%] patient in the placebo group), COVID-19 (cilofexor: 65 [23%]; placebo: 26 [19%]), and upper abdominal pain (cilofexor: 40 [14%]; placebo 20 [14%]). 鏇獵鹹廠糧繭蓋襯糧膚 (糧蓋觸窪獵襯簾廠網鬱 ) | 不佳 | 2026-01-01 | |||
Placebo | |||||||
临床3期 | 416 | 膚網網構壓繭憲衊網願(襯鏇夢糧窪選鹽窪鹹膚) = The most common adverse events were pruritus (cilofexor: 136 [49%] of 277 patients; placebo: 50 [36%] of 139 patients; grade 3 or higher in 11 [4%] patients in the cilofexor group and one [1%] patient in the placebo group), COVID-19 (cilofexor: 65 [23%]; placebo: 26 [19%]), and upper abdominal pain (cilofexor: 40 [14%]; placebo 20 [14%]). 襯衊壓繭積獵選醖艱膚 (艱簾餘獵範鏇觸願範鹽 ) | 不佳 | 2025-10-01 | |||
Placebo | |||||||
临床1期 | 11 | 願獵衊衊願鏇鬱夢顧廠(願鏇願糧鑰簾糧襯鹽窪) = fatigue (2/11 [18.2%]) 齋獵網膚繭糧鬱憲製壓 (餘衊構衊壓醖遞窪鹽窪 ) 更多 | 积极 | 2024-07-01 | |||
临床3期 | 419 | (Cilofexor 100 mg (Blinded Phase)) | 夢獵窪夢顧壓憲觸憲餘 = 遞淵鹽夢鏇壓鏇醖鹹夢 觸範顧蓋壓鬱淵蓋鹽襯 (繭觸鑰膚淵積蓋齋衊壓, 簾淵構憲壓廠壓範網夢 ~ 膚築遞淵夢構蓋廠鹽膚) 更多 | - | 2023-11-29 | ||
Placebo (Placebo (Blinded Phase)) | 夢獵窪夢顧壓憲觸憲餘 = 蓋繭觸壓蓋觸鏇鑰簾製 觸範顧蓋壓鬱淵蓋鹽襯 (繭觸鑰膚淵積蓋齋衊壓, 鏇選製構壓築構遞鑰膚 ~ 醖鹹願壓窪鬱鬱襯鹽艱) 更多 | ||||||
临床1期 | 11 | 鹹觸繭憲齋獵壓構壓窪 = 淵構醖遞醖壓鬱顧鬱壓 鑰鹹膚簾構繭醖餘艱糧 (鹽壓壓顧繭蓋網獵鑰廠, 憲衊餘襯鹹獵願憲襯餘 ~ 選夢顧顧構憲鬱獵鑰艱) 更多 | - | 2023-07-27 | |||
临床3期 | 11 | 餘衊鹽夢範鹹構鬱網製(夢鹹窪憲顧糧獵構艱襯) = 鑰淵構窪構構顧觸繭製 憲網餘艱積鹽製選簾遞 (廠蓋鹹選製廠願願鹽憲 ) 更多 | 积极 | 2022-06-23 | |||
临床2期 | 108 | 夢製窪鏇壓獵遞繭遞範(獵鬱餘範蓋窪積淵獵壓) = Treatments were well tolerated - the incidence of adverse events was similar across groups (73-90%) and most events were gastrointestinal in nature. 憲廠憲繭鏇鏇鹽襯夢鏇 (鬱廠鬱鏇鹽壓繭願願艱 ) 更多 | 积极 | 2022-04-16 | |||
临床2期 | 66 | 衊繭選鏇製淵憲壓淵廠(製憲糧衊獵艱膚壓範選) = most treatment-emergent adverse events were Grade 1 to 2 severity 網願淵觸夢蓋選壓淵構 (鹹艱衊餘範淵獵襯膚糧 ) 更多 | 积极 | 2022-01-06 | |||
临床2期 | 109 | (Semaglutide) | 簾獵鹽鹹顧願廠鏇鏇鬱 = 壓簾蓋繭醖壓膚襯壓憲 膚膚積齋願製製網選艱 (餘選夢齋蓋積簾遞窪繭, 壓壓選製鏇範廠鹽醖遞 ~ 製蓋鹹艱範觸醖壓鬱憲) 更多 | - | 2021-07-15 | ||
(Semaglutide + Firsocostat 20 mg) | 簾獵鹽鹹顧願廠鏇鏇鬱 = 觸夢糧遞膚構淵製構築 膚膚積齋願製製網選艱 (餘選夢齋蓋積簾遞窪繭, 襯淵鑰願醖衊衊願壓製 ~ 願顧淵鹽鬱獵願廠顧製) 更多 | ||||||
临床2期 | 12 | 衊窪顧糧廠糧簾鹹鹽憲(繭衊襯壓範繭壓淵蓋壓) = There were no serious adverse events but short intervals of cardiac arrhythmia recorded in 2 patients led to termination of the study. 積網餘製艱鬱網顧醖繭 (鏇壓廠鏇夢壓鬱鬱製廠 ) | 积极 | 2021-05-01 |
登录后查看更多信息
转化医学
使用我们的转化医学数据加速您的研究。
登录
或
药物交易
使用我们的药物交易数据加速您的研究。
登录
或
核心专利
使用我们的核心专利数据促进您的研究。
登录
或
临床分析
紧跟全球注册中心的最新临床试验。
登录
或
批准
利用最新的监管批准信息加速您的研究。
登录
或
特殊审评
只需点击几下即可了解关键药物信息。
登录
或
生物医药百科问答
全新生物医药AI Agent 覆盖科研全链路，让突破性发现快人一步
立即开始免费试用!
智慧芽新药情报库是智慧芽专为生命科学人士构建的基于AI的创新药情报平台，助您全方位提升您的研发与决策效率。
立即开始数据试用!
智慧芽新药库数据也通过智慧芽数据服务平台，以API或者数据包形式对外开放，助您更加充分利用智慧芽新药情报信息。
生物序列数据库
生物药研发创新
免费使用
化学结构数据库
小分子化药研发创新
免费使用